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ABSTRACT
The monoamine, serotonin, is an important modulator in the central nervous
system. It is believed to participate in a variety of functions ranging from moderating stress,
promoting brain plasticity, and regulating sleep and appetite. Dysfunction of the
serotonergic system has also been implicated in mood disorders and neurodegenerative
diseases. While serotonin is of great interest to the research community, real-time in vivo
serotonin dynamics remain understudied. This is because direct measurement of fast
serotonergic transmission is analytically challenging. In 2009, the Hashemi lab pioneered
the direct measurement of endogenously evoked serotonin using a method called fast scan
cyclic voltammetry (FSCV). FSCV allows for selective detection of serotonin on a time
scale conducive for neurotransmission. This work aims to further our understanding of
serotonergic transmission in healthy and disease states. First, we discuss different methods
investigating the two uptakes systems for monoamine reuptake into the cell (Chapter 2).
Then we review electrochemical serotonin detection and recent findings (Chapter 3). Next,
we evaluate serotonin in a toxicological model of Parkinsonism (Chapter 4). This study
revealed that mice with lesioned dopamine neurons also have lower concentrations of
serotonin in the hippocampus. Furthermore, when given levodopa, dopamine is released at
the expense of serotonin production. Finally, we optimized the serotonin waveform to
improve electrode sensitivity to serotonin (Chapter 5). When measuring the small signals
in the neurodegenerative mice, it became apparent that increased sensitivity was needed
for future experiments. We determined that by extending the serotonin waveform to an
vi

upper limit of 1.3 V compared to the 1.0 V of the traditional waveform, we could improve
serotonin sensitivity while maintaining selectivity. Collectively, this dissertation furthers
our understanding of serotonin in mood disorders and neurodegeneration as well as
improves our electroanalytical techniques for future studies.
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CHAPTER 1
INTRODUCTION
1.1 Chemical Neurotransmission
Until the mid 1900s, there was much debate over whether synaptic transmission
occurred through electrical or chemical means.1 This debate finally culminated with the
confirmation of acetylcholine as a chemical transmitter in the peripheral nervous system
(PNS) in the 1930s.2, 3 Decades later, experiments showed that chemical transmission
occurred in the central nervous system (CNS) as well.4, 5 These chemicals became known
as neurotransmitters, or chemical messengers that are released from one neuron and act
upon the receptors of a second target neuron. Since the 1960s, many different
neurotransmitters and neuroreceptors have been identified, including dopamine, serotonin,
norepinephrine, histamine, glutamate, and gamma aminobutyric acid (GABA) among
many others. These transmitters are further separated into two major sub categories:
classical neurotransmitters and neuromodulators, with neurotransmitters being confined to
the synaptic space and neuromodulators being released via “volume transmission” into the
extrasynaptic matrix.

6, 7

As such, neuromodulators have an effect on multiple neurons.

Understanding the complexities of underlying neurochemical dynamics is fundamental to
accurately diagnosing and treating diseases of the brain. The Hashemi lab uses novel
techniques to study the direct electrochemical detection of multiple neuromodulators, with
a focus on serotonin and histamine.
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1.1.1 The Serotonergic System
Serotonin (5-hydroxytryptamine; 5-HT) is a monoamine that acts primarily as a
neuromodulator in the CNS. It has a wide variety of functions such as moderating anxiety
and stress,8, 9 promoting brain plasticity,10 and regulating sleep and appetite. 11 It has also
been implicated in mood disorders such as depression.12-14 Serotonin is synthesized from
L-tryptophan by the enzymes tryptophan hydroxylase and aromatic L-amino acid
decarboxylase (AADC) in neuronal terminals present in nearly every brain region.15 As
with many other monoamines, serotonin is packaged into vesicles via the vesicular
monoamine transporter (VMAT)15 and released through either synaptic16, 17 or volume
transmission.18 Termination of the signal occurs predominantly by uptake of serotonin back
into the neuron, through transporter proteins. This occurs through two uptake mechanisms
coined uptake 1 and uptake 2 as further discussed in chapter 2. Uptake one is a highaffinity, low efficiency process via the serotonin transporter (SERT), while uptake two is
low-affinity, high efficiency uptake by transporters not specific to serotonin such as the
dopamine transporter (DAT), norepinephrine transporter (NET), organic cation transporter
(OCT), and plasma membrane transporter (PMAT).19-21
Serotonergic cell bodies are located largely in the dorsal raphe nucleus (DRN)
along the midline of the brainstem.15 These neurons project axons to nearly every brain
region, including but not limited to the substantia nigra, hypothalamus, nucleus accumbens,
hippocampus, amygdala and prefrontal cortex.15 There are fourteen different receptors
associated with serotonin separated into four major categories of g-protein coupled
receptors (GPCR) and one ligand-gated ion channel receptor.22 The 5-HT1 receptor group
consists of five subtypes of GPCRs: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F. These
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receptors inhibit intercellular adenylyl cyclase and open K+ channels. 5-HT1A, 5-HT1B, and
5-HT1D also act as autoreceptors located in the membrane of the presynaptic neuron,
providing a negative feedback loop that inhibits serotonin release.23-27 There are three
GPCR receptors in the 5-HT2 receptor family; 5-HT2A, 5-HT2B, and 5-HT2C. This family
of receptors stimulates phospholipase C and are considered excitatory in nature. 5-HT4, 5HT6, and 5-HT7 belong to a family of receptors that activate the adenylyl cyclase pathway.
5-HT3 receptors are the sole ligand-gated ion channel serotonin receptor. Activation of this
receptor causes rapid neuronal depolarization.28
This study will focus mainly on serotonergic projections to the CA2 region of the
hippocampus. This area, along with the CA3 region is moderately and evenly innervated
by serotonin terminals.

29

Furthermore, patients with major depressive disorder (MDD)

exhibit a reduction in CA2/CA3 volume,30 making it of particular interest in the study of
depression.
1.1.2 Role of Serotonin in Neurodegeneration and Psychiatric disorders
The serotonergic system is implicated in many different psychiatric and
neurodegenerative disorders such as depression,12-14, 31 anxiety,8, 9, 32, 33 schizophrenia,34
Parkinson’s disease (PD),35-37 and Alzheimer’s disease38-40 among many others. Of
particular interest in this study is serotonin’s role in both depression and PD. Serotonin was
first associated with depression and mood regulation following the observation that
serotonin and norepinephrine depletion sometimes resulted in depressed mood.12 As the
antidepressant effects of extrasynaptic monoamine increasing compounds such as
monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) were
discovered, the connection between monoamines and depression became more accepted,
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eventually resulting in the monoamine hypothesis of depression.41, 42 This hypothesis states
that one or a combination of the three major monoamines (serotonin, dopamine, and
norepinephrine) provide the underlying biological basis for MDD. This hypothesis was
further narrowed to the serotonergic hypothesis of depression following the development
of the selective serotonin reuptake inhibitor (SSRI).14, 43 SSRIs act by blocking the SERT
and preventing reuptake. This causes serotonin to remain in the extracellular space for
longer periods of time. Further evidence for serotonin’s role in MDD, was presented by
Caspi et al.44 In this study, patients with a polymorphism in the SERT gene presented more
depressive symptoms following stressful life events than those without the alteration.
Furthermore, depletion of tryptophan, the precursor molecule for serotonin, results in a
relapse in depressive symptoms for patients who have previously suffered from
depression.45, 46
PD is a neurodegenerative disorder traditionally associated with extensive
dopaminergic cell loss in the midbrain.47 The underlying dopaminergic chemistry
associated with the motor symptoms of PD such as tremors, bradykinesia, and rigidity have
been extensively studied. However, the nonmotor systems such as depression and anxiety
are less well understood, leading to difficulty in treatment. One reason for inadequate
treatment in PD-associated depression, is an insufficient study of antidepressant response
in PD patients.48 Like with major depression, SSRIs are the most commonly prescribed
antidepressants for PD patients, because they are typically tolerated well by the elderly.49
However, there are conflicting reports on whether SSRIs are safe for use among PD
patients50-52 or whether they are effective in treating PD-associated depression.53-57 Studies
targeting the other monoamine systems of norepinephrine and dopamine have produced
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equally contradictory results. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and
TCAs that act on the combined serotonin and norepinephrine systems present mixed
efficacy and are considered less desirable for patients with comorbidities. 54-56, 58 While
dopamine agonists have produced more promising results,59 they are still wildly
understudied in the context of PD-associated depression. Furthermore, dopamine
replacement through Levodopa (L-DOPA) has been shown to be largely ineffective in
treating depressive symptoms,60-62 sometimes even worsening symptoms in PD-associated
depression.63, 64 The discrepancies across these studies may be due to a variety of factors
such as different metrics for assessing depression, lack of double-blind studies, and
different experimental timelines. However, because of the conflicting nature of these
studies, it is vitally important that we understand the underlying neurochemical
mechanisms of PD-associated depression.
While L-DOPA therapy is the gold standard in treatment of the motor symptoms of
PD, its inefficacy in treating the nonmotor symptoms suggests the involvement of other
monoamine systems, specifically the serotonergic system. In recent years, serotonin has
gained interest as a molecule of importance in PD. Although variable, markers of serotonin
loss have been observed along with dopaminergic loss.36,

37, 65, 66

Furthermore, it is

suggested that serotonergic neurons are affected before dopaminergic neurons as Lewy
bodies, the abnormal protein aggregates found in neuronal cells during PD, have been
found to aggregate in serotonergic neurons as early as stage two of the disease. 67 This,
along with serotonin’s role in depression, supports the finding that PD patients may suffer
from depression years before motor symptoms first appear.68
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The serotoninergic system is also associated with levodopa induced dyskinesia
(LID).69-73 This is a movement disorder that occurs after chronic L-DOPA administration,74
presenting in over 50% of patients treated for a duration of at least five years.75 L-DOPA,
the dopamine precursor, is administered as a form of dopamine replacement because it
crosses the blood brain barrier (BBB) far easier than dopamine. The intention is that LDOPA will cross the BBB, be uptaken by dopaminergic neurons, converted to dopamine
by AADC, and then released resulting in an increase in dopamine in the extracellular space.
However, dopamine neurons are not the only cells capable of L-DOPA uptake.
Serotonergic neurons not only take up L-DOPA,76, 77 but contain both the AADC necessary
for dopamine synthesis78 and the packaging and release machinery needed for dopamine
exocytosis.79 It is believed that the release of dopamine from these neurons comes at the
expense of serotonin production and release,80 and is responsible for the disjointed
movements seen in LIDs.69,

72

This decline in serotonin release, may in part also be

responsible for the worsening of depression symptoms often seen following L-DOPA
administration. Therefore, the study of the serotonergic system is of great interest in
understanding the underlying chemical mechanisms in both PD-associated depression and
LIDs.
1.2 Evaluation of Neurodegeneration in Animal Models of Parkinsonism
Creating animal models of PD is particularly difficult because the pathophysiology
of PD is not fully understood, resulting in animal models that do not often translate well to
clinical studies.81 Rodent models are most widely used, as they are relatively inexpensive,
readily available, and mimic many aspects of PD. Often parkinsonism is induced in an
animal model either through an environmental toxin or genetic manipulation. Genetic
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models often target genes associated with overexpression of -synuclein,82-85 a protein
associated with improper aggregation in neurons during PD, or by targeting autosomal
recessive genes present in patients with familial PD (i.e. Parkin, PINK1, LRRK2). 86-88
While these have provided valuable insight into the progression of PD, these models are
limited in the fact that the majority of PD is sporadic, with only 10 to 20% linked to genetic
mutations.87 Environmental toxins such as 6-hydroxydopamine (6-OHDA), rotenone,
paraquat, and 1-methyl-4-phenyl-1,2,3,6-tetrahdropyridine (MPTP) have been used widely
over the years as they cause an extensive loss of striatal dopamine neurons as well as mimic
the motor symptoms of PD.89-93 However, these models do not provide a true pathogenesis
for PD as they often cause acute not gradual neurodegeneration. They do, however, provide
important information on the neurochemical underpinnings associated with PD.
Administration of MPTP is one of the most common and well documented methods
of inducing Parkinsonism. Its discovery occurred following a “medical mystery” where the
patient had ingested a synthetic heroin and presented an acute onset of symptoms typical
of PD.94 It was later discovered that after crossing the BBB, MPTP is converted to the toxic
ion 1-methyl-4-phenylpyridinium (MPP+) by astrocytes.95 It is then uptaken into neurons
by DATs96 where it inhibits complex I in isolated mitochondria.97 This causes a decrease
in adenosine triphosphate (ATP) production and eventual dopamine neuronal cell death.
Protocols for MPTP administration vary wildly from study to study making it difficult to
compare results, however, one of the more common protocols involves acute peripheral
injections of a high concentration of MPTP. This protocol not only produces a substantial
decrease of striatal dopamine by at least 40-50%,

98, 99

but also a decrease in serotonin

concentrations across multiple brain regions, with an emphasis on the frontal cortex.100-102
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Further studies are of extreme importance in understanding the changes in serotonin in
additional brain regions (i.e. hippocampus) following MPTP induced parkinsonism. This
topic will be further explored in Chapter 5.
1.3 Methods of Measuring Neurotransmitters in the Brain
Neurotransmitter detection is implemented through a variety of methods, including
microdialysis,103-105 fluorescence,106 and electrochemical techniques.107-109 When studying
neurotransmission, there are four important criteria that a technique must satisfy to be a
sufficient detection platform: size, sensitivity, selectivity, and speed.110 Each of these
techniques have their respective benefits and limitations that must be accounted for. This
dissertation will focus on solely on electrochemical methods of detection. Electrochemical
methods have long been used to study various neurotransmitters in vivo. Throughout the
years, different analytical techniques such as amperometry, potentiometer, and
voltammetric methods have been utilized.109 These methods allow for direct detection of
analytes through measurement of oxidation and reduction at the electrode surface.
Specifically, the technique of Fast-Scan Cyclic Voltammetry (FSCV) is of interest because
it satisfies all four of the criteria stated above.
1.3.1 Fast-Scan Cyclic Voltammetry
Fast scan cyclic voltammetry (FSCV) is an electrochemical technique that directly
and selectively detects an analyte of interest through the rapid oxidation and reduction at
the electrode surface. This technique was first utilized in the mid 1980s by R. Mark
Wightman and Julian Millar for the detection of dopamine in the striatum of anesthetized
rats.107 Like with traditional cyclic voltammetry, FSCV is performed by linearly increasing
the potential applied between a working and a reference electrode until the designated
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upper limit is reached. The applied potential is then decreased linearly until it returns to the
original starting potential. This change in potential is called a waveform and can be adapted
and optimized to measure different analytes. One major difference in FSCV compared to
traditional cyclic voltammetry is that the scan rate, or the change in the rate of voltage over
time, is significantly higher (>100 V/s compared to <100 mV/s). This allows for analyte
detection on a time scale conducive for neurotransmission, making it a prominent technique
for chemical detection in the brain. However, one disadvantage of increasing the scan rate
is that faster scan rates produce large non-faradaic capacitive currents. These non-faradaic
currents are large enough to obscure the faradaic signal produced by the analyte. This
necessitates that FSCV must be background subtracted to remove the capacitive current,
requiring a change to be induced in the system. In vivo this is usually done by stimulating
neurotransmitter release through electrical, optical, behavioral or pharmacological
methods.108, 111-113
Traditionally, FSCV uses a type of electrode called a carbon-fiber microelectrode
(CFM), first used by Ponchon and Pujol.114 Carbon is a desirable electrode material for
electrochemical detection because of its low cost, rich surface chemistry, and
biocompatibility. Additionally, many bioamines such as serotonin, dopamine, and
histamine are readily oxidized within its potential window. Most importantly, however, is
that carbon can easily be crafted into microelectrodes with a typical diameter of 7-10 µm
and a length ranging from a scale of nanometers to a few hundred micrometers.108, 115 This
small electrode size not only allows for minimal damage to brain tissue but serves to reduce
the capacitive or background currents.116 Often CFMs are modified to increase sensitivity
or selectivity using polymers or ionophores,108,
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117-119

the most common of these

modifications being the electrodeposition of the cation exchange polymer, Nafion. 108, 120
Nafion provides increased sensitivity to positive molecules such as serotonin and dopamine
while also repelling negative molecules like ascorbic acid and 5-HIAA.121, 122

Figure 1.1. FSCV Scheme. A) Representative colorplot for the oxidation and reduction of
serotonin using FSCV. Extraction of the vertical dotted line reveals the CV characteristic
of serotonin (red star), while the horizontal dotted line reveals the biologically relevant
current vs time curve (blue star).
More recent advancements in FSCV have led to the measurement of dopamine in
awake and freely moving animals,
dopamine, i.e. serotonin

108, 125,

melatonin 130, and copper (II)

123, 124

as well as the detection of analytes other than

histamine

118, 131.

126, 127,

adenosine

128,

hydrogen peroxide

129,

While there are many different analytes that can be

detected using FSCV, the scope of this dissertation will focus on the measurement of
serotonin. Exogenous serotonin was first measured in vivo using FSCV by Jackson et al in
the rat caudate putamen.125 A decade later, Hashemi et. al measured evoked endogenous
serotonin in vivo.108
We measure serotonin by placing a Nafion-coated CFM in the CA2 region of the
hippocampus compared to a pseudo Ag/AgCl reference electrode placed in the
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contralateral hemisphere. An optimized serotonin waveform125, 132 is applied to the working
electrode surface at a frequency of 10 Hz, meaning that the waveform is applied once every
100 ms. Each time the waveform is applied, serotonin is oxidized at approximately 0.7 V,
producing a current vs. voltage curve also known as a cyclic voltammogram (CV). These
CVs are stacked in order of acquisition to form a 3D colorplot. For ease of viewing, this
colorplot is visualized in 2D with the x-axis representing time, the y-axis representing
voltage, and the third dimension of current represented by false color as shown in Figure
1A. Taking a vertical section of the colorplot reproduces the CV which is important for
identification of the target analyte, while taking a horizontal section produces a current vs
time curve. This current vs time curve relays the biologically relevant information about
how the analyte is changing over time. As previously mentioned, FSCV is a background
subtracted technique, requiring a changed to be evoked in the system. To induce this
change, an electrical stimulating electrode is placed in the medial forebrain bundle (MFB),
a dense bundle of axonal fibers that projects to a variety of brain regions. Following the
acquisition of the serotonin signal, current is converted to concentration by a preestablished calibration factor.108
1.3.2 Fast Scan Controlled Adsorption Voltammetry
As previously discussed, one major disadvantage of FSCV is that it is a background
subtracted technique. To address this, the technique of Fast Scan Controlled Adsorption
Voltammetry (FSCAV) was developed.133-135 FSCAV is a technique that allows for
determination of an absolute concentration of the analyte of interest. It consists of three
steps: 1) Minimized adsorption 2) Controlled adsorption and 3) Rapid Oxidation of the
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adsorbed analyte. During the first step, the waveform is applied at a high frequency of 100
Hz for 2 seconds to minimize adsorption to the electrode surface. In the second step, the
electrode is held at the resting potential for 10 seconds to allow for adsorption to the
electrode surface. Finally, the waveform is reapplied at a frequency of 100 Hz to oxidize
the analyte that has adsorbed on the electrode surface. The area under the curve is integrated
for the first CV indicative of serotonin, producing charge. The electrode is then postcalibrated to obtain absolute serotonin concentrations.

Figure 1.2. FSCAV Scheme Schematic for the three steps of FSCAV: 1) Minimized
adsorption 2) Controlled adsorption and 3) Oxidation of absorbed species.
1.4 Scope of Dissertation
This dissertation aims to use novel electrochemical techniques to evaluate the
serotonergic system in the context of depression and Parkinson’s Disease. I first provide
12

an overview of the two uptake systems that regulate termination of monoamine signaling
(Chapter 2) as well as a review of the role of serotonin and histamine in neuroinflammation
using fast electrochemical detection (Chapter 3). This is followed by an evaluation of
serotonin response to SSRIs and L-DOPA in the context of Parkinson’s Disease (Chapter
4). Finally, I discuss the application and optimization of a novel serotonin waveform to
improve electrode sensitivity (Chapter 5). An outline of this dissertation is described
below.
Chapter 1: Introduction. This chapter provides an introduction to the topics discussed
throughout this dissertation.
Chapter 2: Review of Experimental Methods for Investigating the two uptakes
systems in the brain. This chapter provides a review of the two uptake mechanisms
identified for the monoamines dopamine, serotonin, and norepinephrine.
Chapter 3: Review of Mathematical Models of Serotonin, Histamine, and Depression.
This chapter provides a review for the use of voltammetric techniques in the measurement
of serotonin and histamine in depression and neuroinflammation.
Chapter 4: A Real Time Voltammetric Study of Serotonergic Signaling in a
Toxicological Model of Parkinson’s Disease. This chapter describes the voltammetric
and mathematical investigation of serotonin in a toxicological model of PD. I administered
two of the pharmaceuticals most often used in the treatment of PD: SSRIs and L-DOPA to
determine the efficacy of these drugs on serotonergic release and reuptake.
Chapter 5: Overoxidation via a Novel Waveform Increases Electrode Sensitivity to
Serotonin This chapter describes optimizations made to the serotonin waveform to
improve sensitivity. I extended the waveform upper limit from a potential of 1.0 V to 1.3
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V in vitro and in vivo. This improved electrode sensitivity to serotonin while maintaining
selectivity.
Chapter 6: Conclusion The final chapter summarizes the conclusions of my work and
highlights

future

directions

of

research

neurodegeneration.
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CHAPTER 2
EXPERIMENTAL METHODS FOR INVESTIGATING UPTAKE 2
PROCESSES IN VIVO1

1Buchanan,

A. M.,* Parke, B.,* Hashemi, P. Experimental Methods for Investigating

Uptake 2 Processes In Vivo. In Daws, L.C., (Ed.), Organic Cation Transporters in CNS,
Springer. Accepted for publication
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2.0 Abstract
Neuromodulators are critical regulators of the brain’s signaling processes, and thus
they are popular pharmacological targets for psychoactive therapies. It is clear that
monoamine uptake mechanisms are complicated and subject to multiple uptake
mechanisms. Uptake 1 describes uptake of the monoamine via its designated transporter
(SERT for serotonin, NET for norepinephrine and DAT for dopamine), whereas Uptake 2
details multiple transporter types on neurons and glia taking up different types of
modulators, not necessarily specific to the monoamine. While Uptake 1 processes have
been well-studied over the past few decades, Uptake 2 mechanisms have remained more
difficult to study because of the limitations in methods that have the sensitivity and
spatiotemporal resolution to look at the subtleties in uptake profiles. In this chapter we
review the different experimental approaches that have yielded important information
about

Uptake

2

mechanisms

in

vivo.

The

techniques

(scintillation

microspectrophotometry, microdialysis, chronoamperometry and voltammetry) are
described in detail, and pivotal studies associated with each method are highlighted. It is
clear from these reviewed works that Uptake 2 processes are critical to consider to advance
our understanding of the brain and develop effective neuropsychiatric therapies.
2.1 Introduction
Modulators in the brain mediate excitatory and inhibitory chemical processes thus
these messengers are ideal pharmacological targets to restore pathophysiological chemical
imbalances. Transporters have been a major therapeutic focus because of their significance
in regulating extracellular neurotransmitter levels. As such, agents have traditionally aimed
to selectively target one or more transporters
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136, 137.

However, it is becoming clear that

uptake mechanisms are much more complicated than one protein one substrate. 138 There
are currently 2 recognized uptake systems;138 Uptake 1 is the designated protein uptake
transporter for the specific modulator on neurons (SERT for serotonin, NET for
norepinephrine and DAT for dopamine) and Uptake 2 is a combination of other
transporters, not specific to the monoamine, on neurons and glia, including the organic
action transporters (OCTs) and plasma membrane transporters (PMATs). 19-21 This more
complex uptake profile may account for the clinical variability of reuptake inhibitor
therapies.139 Therefore, to improve drug efficacy it is critical to better understand how
substrates interact with different uptake transporters. Uptake 1 processes have been studied
in great detail over the last few decades, while uptake 2 mechanisms remain less defined.
In general, it is difficult to study uptake mechanisms due to the spatial and temporal
limitations of analytical technologies to capture multiple uptake mechanisms in intact
tissue. In this chapter, we review the different experimental approaches that have yielded
important information about Uptake 2 mechanisms in vivo. The techniques utilized
(scintillation spectrometry, microdialysis, chronoamperometry and voltammetry)140-143 are
described in detail and major findings applying these methods are highlighted. It is clear
from the works reviewed here that Uptake 2 processes are critical to consider for advancing
our understanding of the brain and developing more efficacious neuropsychiatric therapies.
2.2 Methods for Investigating Uptake 2 Processes In Vivo
2.2.1 Scintillation Microspectrophotometry
It was clear by the mid-1960s that neurotransmitters accumulated in different brain
regions.144-146 This phenomenon hinted towards specific mechanisms that enable selective
aggregation of molecules. At the time, methods to study such mechanisms were limited.
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Autoradiography, whereby radio-labelled species were patterned via visualization of the
radioactive component, was a popular method to study neurotransmitter localization. In
1967, Aghajanian and Bloom injected 3H-serotonin into the lateral ventricle of the rat and
found, via autoradiography, that low concentrations of radiolabelled serotonin localized in
nerve terminals in periventricular regions.147 A series of further studies found serotonin
localization in catecholaminergic neurons in the vas deferens, 148 pineal gland,149, 150 and
multiple other unspecified brain regions,6, 151. A seminal study, by Blackburn et. al. in
1967, showed evidence for active uptake of serotonin into tissue slice preparations using a
method called scintillation spectrophotometry.152 Here synaptosomes were isolated from
brain homogenates and two different groups were incubated at 0° and 37°C with 5 µg mL1

of 14C-serotonin. A toluene scintillator (substance that converts radioactivity (i.e. from

14C-serotonin)

to visible light) was added to the incubated preparations to measure the

presence of 14C-serotonin as counts per time. When subtracted from the counts per time at
0°C, the preparation at 37°C showed significant uptake of 14C-serotonin. The group found
a Vmax of uptake of 770 µg 5min-1 g-1 and a Km of 0.57x10-6 M. This finding was verified
by others using the same method.145, 153 Snyder and co-workers explored serotonin uptake
in more detail in 1970. They compared serotonin uptake kinetics to norepinephrine uptake
kinetics across various brain regions.140 Figure 2.1 illustrates Snyder’s experiment.
Here striatal and hypothalamic regions were extracted from rat brains, homogenized in
solution and incubated at 37°C with different concentrations of 3H-serotonin. Using
scintillation spectrophotometry the group found, in both regions, two distinct mechanisms
of uptake evidenced by two slopes in a Lineweaver-Burk plot. These two mechanisms
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consisted of a high affinity (Km1: 1.7x10-7 M), low efficiency (Vmax1: 1.12 µmol min-1 g-1)
mechanism and a low affinity (Km2: 8.0x10-6 M), high efficiency mechanism (Vmax2: 26.6
µmol min-1 g-1). Thus was born Uptake 1 and 2. The group went on to show evidence for
different serotonin receptor types

154

and how pharmacological manipulation alters their

binding efficiencies.155

Figure 2.1. Illustration of Snyder’s 1970 scintillation spectrometry experiment.140 Snyder
and colleagues extracted and homogenized hypothalamic and striatal regions of rat brains.
The brain homogenates were incubated with radiolabeled serotonin (3H-serotonin) at 37°C
at various concentrations and durations. The samples were then washed, and a toluene
scintillator was added to convert the radioactive photons to visible light, which were
measured via spectroscopy. The Lineweaver-Burk plots are reproduced with permission
from Aspet Journals. Created using Biorender.com
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2.2.3 Microdialysis
Scintillation spectrometry, while shedding important light on two uptake
mechanisms, is not amenable to in vivo work. Microdialysis, however, is a well-established
in vivo method that measures neurochemicals, where a micro-dimensional probe is directly
implanted into brain tissue and infused with a perfusion fluid that mimics the osmotic
character of interstitial fluid. At the distal end of this probe is a semipermeable, nanoporous membrane. The cut-off of this membrane can be designed to allow exchange of
smaller brain chemicals, but not larger bacteria/viruses. As the perfusate travels through
the probe, exchange occurs, and the dialysate is collected for separation and secondary

Figure 2.2. A general illustration of a microdialysis experiment. A microdialysis probe is
implanted into the brain area of interest and perfused with artificial cerebral spinal fluid.
Neurochemicals in the extracellular space diffuse into the probe and are carried out via the
dialysate. The dialysate is collected, separated, usually via HPLC, and analyzed with a
secondary method. Created using Biorender.com
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analysis. This separation is most often carried out via HPLC 156, 157 with the analysis with
US/VIS,158-160 electrochemical,161-164 and mass spectroscopy detection.165, 166 Figure 2.2
is an illustration of the method.
In the early 90s, Wurtman and colleagues used microdialysis in the rat striatum and
administered two catechol-O-methyltransferase (COMT) inhibitors i.p.167 The group
found that these inhibitors increased dialysis levels of 3,4-Dihydroxyphenylacetic acid
(DOPAC) and dopamine. Given that COMT is not localized in presynaptic dopaminergic
terminals, this work implied a role for glial cells and non-dopaminergic neurons (i.e. via
Uptake 2) in dopamine metabolism. This was foundation work for studying Uptake 2 of
dopamine via microdialysis. Käenmäki et al. investigated the effect of DAT, NET, and
MAO inhibitors on dopamine concentrations in the prefrontal cortex (pFC) of COMT-k/o
mice.168 The group found that COMT contributed to over half of the dopamine clearance
in the pFC, showing that Uptake 2 played a significant role for dopamine clearance in the
pFC. Another role for Uptake 2 was highlighted by Cui et al. who hypothesized that OCT3
(major Uptake 2 transporter type) bidirectionally regulates 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) and methamphetamine’s damaging effects on dopamine
neurons.169 The group used microdialysis to measure dopamine, homovanillic acid (HVA),
DOPAC and 1-Methyl-4-phenylpyridinium (MPP+) following MPTP administration in
OCT3 knock-out mice. Dopamine, HVA and DOPAC were also measured following
administration of methamphetamine. The group found that deletion of OCT3 protects
against MPTP induced dopaminergic neurodegeneration by hampering the release of
MPP+ from astrocytes. However, OCT3 deletion decreased the removal rate of
extracellular dopamine following methamphetamine, causing additional damage to
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dopaminergic terminals. These opposing effects showed the bidirectional control of this
damage process by OCT3. A seminal paper by Gasser, Mantsch and colleagues showed
the behavioral significance of Uptake 2.170 Corticosteroid, (which blocks OCTs and
PMATs), was shown to reinstate drug seeking behavior after extinguishment. The group
postulated that this could be due to inhibition of dopamine metabolism or due to transporter
mediated clearance. Taken together, these dopamine microdialysis studies shed light on
the physiological and behavioral importance of Uptake 2 processes.
Microdialysis has also been used to study Uptake 2 in the context of serotonin.
Feng et al. measured serotonin in the medial hypothalamus following administration
of OCT3 inhibitor decynium-22 (D-22).141 They found that D-22 administration increased
local concentrations of serotonin in the medial hypothalamus in a reversible and dosedependent manner. Adding significance to this work, they found that the highest dose of
decynium-22 resulted in an increase in grooming behavior. Further highlighting the role
of serotonin in Uptake 2 mediated behavior, Renner and Lowry found that agents that
interfere with OCT3 transport (corticosteroid and normetanephrine) increased serotonin
concentration in the central amygdala under stress but not under home cage conditions,
suggesting a role for OCT3 uptake of serotonin under stress condition. 171 Behavioral
studies were extended to depression when Rahman et al. measured serotonin and
norepinephrine in the rat frontal cortex and found that inhibiting both Uptake 1 and 2
elicited a greater increase in norepinephrine than inhibiting either uptake mechanism
alone.172 The group used this finding as a basis to suggest that Uptake 2 mechanisms are
involved in antidepressant effects (a notion explored by Lyn Daws and colleagues with
chronoamperometry (vide infra)).
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In summary, microdialysis has shed important light on mechanistic, behavioral and
pharmacological aspects of Uptake 2.
2.2.4 Chronoamperometry
High-speed chronoamperometry is an electrochemical technique that applies a
square wave potential to a working electrode, often a carbon fiber microelectrode. The
potential is stepped from an initial, resting, potential to a potential sufficient for oxidation
or reduction of analytes. The current resulting from this step is diffusion driven by analyte
transfer from bulk solution to the electrode surface. 173 Following this potential step, the
current decay is measured as a function of time.174 The voltage is then stepped to a potential
where the inverse REDOX reaction occurs. Chronoamperometry is often used to measure
kinetics of chemical reactions,175, 176 diffusion coefficients,177, 178 and significant to this
chapter, the method has been successfully implemented to study various monoamine
systems in the brain.179-181
The vast majority of chronoamperometry studies on Uptake 2 focus on measuring
serotonin. In 1998 chronoamperometry was first used to provide evidence of multiple
uptake mechanisms.182 SSRI administration in rats slowed serotonin clearance in the
dentate gyrus (DG) and the CA3 region of the hippocampus, whereas a NET inhibitor
slowed clearance only in the DG. A detailed study by Daws and colleagues in 2005 utilized
the method to calculate the kinetics of uptake.183 The group inserted multi-barrel carbon
fiber microelectrodes into 4 different brain regions (dorsal raphe nucleus, dentate gyrus,
CA3, and corpus callosum). They applied increasing concentrations of serotonin (Figure
2.3) and the kinetics of serotonin clearance were calculated (inset graph on bottom right of
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figure). The group clearly showed two mechanisms for serotonin uptake. The first being
the high affinity, low capacity (Uptake 1) uptake associated with SERTs and the second
being the low affinity, high capacity uptake of NET (Uptake 2). The group then focused
on OCTs by using serotonin transporter (5HTT) mutant mice with impaired 5HTT

Figure 2.3. Illustrative depiction of Daws’ chronoamperometry experiment from 2005.
Electrochemical recordings were taken, with high-speed chronoamperometry, in the dorsal
raphe nucleus (DRN), corpus callosum (CC), CA3 region of the hippocampus (CA3) and
dentate gyrus (DG). Exogenous serotonin was pressure-injected into the extracellular space
near the electrode (300 µm) and variances in uptake kinetics of serotonin were observed
across the four brain regions. Specific transporters responsible for serotonin uptake were
discerned by pharmacological manipulation.183 Reproduced with permission from
Elsevier. Created using Biorender.com
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expression.184 Serotonin and histamine clearance were measured in the CA3 region of the
hippocampus.
In control mice, no detectable contribution of OCTs was measured for serotonin or
histamine uptake. However, in 5HTT deficient mice, OCTs contributed to both serotonin
and histamine uptake, showing their ability to uptake these analytes in the absence of
SERTs. Further attesting to OCTs ability to uptake serotonin, decynium-22 (D-22)
administration has antidepressant-like effects in 5-HTT mutant mice but not control mice
as assessed by the tail suspension test. This idea was investigated in more depth in the
following study.185 The group found that D-22 enhanced the effects of fluvoxamine (SSRI)
on serotonin clearance and importantly increased antidepressant effects on behavior. A
final study of note was the investigation of the role of HPA axis activation on serotonin
clearance,186 whereby serotonin was measured after repeated swim paradigms in mice.
Serotonin clearance was likely reduced following these repeated swim paradigms due to
release of corticosterone by HPA activation, resulting in inhibited serotonin clearance by
OCT3. This method, thus, has been used in versatile and elegantly designed studies to
provide a rich body of work on Uptake 2 processes.
2.2.5 Fast Scan Voltammetry
Concurrent with these chronoamperometry studies, another electrochemical
method, namely voltammetry, has been used to uncover important information about
parallel uptake mechanisms. Fast-scan cyclic voltammetry (FSCV) applies an
electrochemical waveform, at very fast scan rates (typically > 400 Vs -1), to a carbon fiber
microelectrode which rapidly captures redox processes at the electrode surface. The
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positions of the redox peaks identify analytes of interest and the magnitude of these peaks
over time quantify analytes.
Wightman and colleagues, who pioneered FSCV, first found evidence for different
kinetics governing dopamine uptake in the striatum and the nucleus accumbens and
attributed these differences to heterogeneity in dopamine overflow.187-190 Adrian Michael
and his group found domain specific dopamine signatures in different parts of the
striatum.191,

192

Specifically, they found ‘fast’ and ‘slow’ release profiles that, like

Wightman’s early findings, were correlated with ‘fast’ and ‘slow’ uptake curves.193 The
group modelled these responses 194 and suggested that the distinctions in uptake were due
to region dependent variations in basal levels of dopamine; functionally dependent on
differing levels of autoinhibition.195 Similar differences in uptake profiles were found in a
collaborative study between Sara Jones and Paul Gasser. In this work, FSCV revealed
slower uptake rates for dopamine in the basolateral amygdala (BLA) compared to the
NAc.196 These researchers explained their findings via contrasting transporter densities
between the regions. Specifically, despite similar levels of OCTs in these brain areas, more
DATs were found in the NAc, where faster dopamine uptake profiles were recorded.
FSCV has traditionally been applied to dopamine detection, however our group has
pioneered the application of this method to serotonin. Serotonin FSCV is fundamentally
more challenging than that of dopamine FSCV. Serotonin is released at much lower levels
than dopamine, meaning that a more sensitive probe is needed with a lower limit of
detection.197 Additionally, serotonin metabolites foul the electrode surface, reducing the
probe’s analytical performance.108 The modification of the carbon surface with a thin layer
of Nafion circumvents these issues by increasing preconcentration of the positively charged
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serotonin ions and repelling the negatively charged serotonin metabolites. This dual effect,
in conjunction with a serotonin specific waveform,198 adheres enough analytical power to
FSCV to measure very low concentrations of evoked serotonin in vivo (~10s of nM). In
2014 we saw two distinct uptake curves for serotonin in the substantia nigra, pars reticulata
(SNr) with the same stimulation of the medial forebrain bundle.199 These two curves had
two discrete slopes of clearance which were present to varying degrees depending on the
microenvironment of the electrode. We termed these responses fast, slow and hybrid to
denote each of the two curves (fast and slow) and a combination of the two (hybrid), Figure
2.4.

Figure 2.4. Representation of the fast, slow and hybrid signals recorded and kinetically
modelled by Wood et al. 2014. These responses were recorded via FSCV in the SNr of a
mouse and converted to concentration over time with a predetermined calibration factor.
This figure was adapted from Wood et al. 2014 and used with permission from ACS
Publications. Created using Biorender.com
Kinetic modelling of the in vivo responses found two distinct sets of MichaelisMenten parameters were necessary to fit the data (Equation 1). In this equation, S(t) is the
extracellular concentration of serotonin in the SNr, R(t) is the rate of release and A(t) is the
fraction of stimulated autoreceptors. The terms α and β were 0 and 1, respectively, for fast
uptake curves and vice versa for slow curves. For these parameters were calculated to be
27

Vmax1 17.5 nM s-1, Km1 5 nM which represents a low efficiency, high capacity system
(Uptake 1) and Vmax2 780 nM s-1, 170 nM Km2, representing a high efficiency, low capacity
system (Uptake 2). Administration of escitalopram, a selective serotonin uptake inhibitor
(SSRI), largely inhibited Uptake 1 and, to a lesser extent, Uptake 2, which highlights
Uptake 1 is controlled by the SERTs.

(1)
Our serotonin signals in the medial prefrontal cortex (mPFC) mirrored Wightman
and Michael’s dopamine signals in the striatum. Specifically, we found that serotonin
overflow (or evoked release) was strongly connected to uptake kinetics.200 When the CFM
was placed in layers 1-3 of the mPFC, a single evoked release peak was observed with a
hybrid, Uptake 1 and 2, clearance profile. When the electrode was placed in layers 5-6 of
the mPFC, a double evoked event was often observed. The first peak resembled the single
peak (observed in layers 1-3) release and uptake kinetics while the uptake of the second
profile was attributed to Uptake 1. From these data, V max1, Km1, Vmax2 and Km2 were
calculated to be 19.25 nMs-1, 5 nM, 780 nMs-1 and 170 nM, respectively. It is important to
note that these values are almost identical to those derived from data taken in the SNr.199
In addition to the SNr and mPFC, we extended our measurements to encompass the
hippocampus and compared the responses. We found distinctly different responses in these
three areas as seen in Figure 5 that shows our experiment.143 By mathematically modelling
the responses we were able to attribute the differences in uptake profiles to the relative
contribution of Uptake 1 and 2 to the electrochemical signal. This allowed us to
hypothesize that the SNr and mPFC have higher densities of SERTs given the larger
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Uptake 1 (slow uptake) component, and confocal imaging verified this. To strengthen this
hypothesis, we used an additional method, fast scan-controlled adsorption voltammetry
(FSCAV).
During FSCV experiments, each time the serotonin specific waveform is applied to
the electrode, a large capacitive current is discharged that masks the faradaic current. Thus,

Figure 2.5. Illustration of the Abdalla et al. 2020 experiments. The CFMs were
electropolymerized with a thin layer of Nafion 108 prior to implantation into the brain. The
serotonin wave form 198 was applied to the CFMs at 10 Hz during experiments. CFMs were
placed in either the medial prefrontal cortex (mPFC), substantia nigra pars reticulata (SNr)
or CA2 region of the hippocampus (CA2) and stimulated release of serotonin was recorded
over time. Two signals from the mPFC showed Uptake 1 (fast decay) and Uptake 2 (slow
decay), with the orange trace exhibiting Uptake 1 and the red trace showing both Uptake 1
and 2. The green trace, recorded in the SNr showed a hybrid response, while the blue trace
from the CA2 showed properties of Uptake 1 only.
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FSCV relies on background subtraction to discern faradaic current signatures associated
with specific molecules. This background subtraction inhibits ambient measurements to be
made via FSCV. Fast scan controlled adsorption voltammetry (FSCAV) was developed to
measure ambient concentrations of neurotransmitters in the extracellular space.133,

201

FSCAV implements the specific waveform for each neurochemical with a modified

Figure 2.6. Representative illustration of the waveform application scheme associated with
FSCAV for serotonin detection. A CFM is lowered into the brain region of interest and,
for each measurement, the serotonin waveform is applied at a high frequency (100 Hz) for
2s to minimize any species from adhering to the CFM surface, then a holding potential of
0.2 V is applied for 10s to allow for species to adsorb to the carbon surface. The waveform
is finally re-applied at 100 Hz for 18s to rapidly reduce and oxidize the adsorbed
electroactive species. A representative color plot for a serotonin FSCAV measurement is
shown below the cartoon. Created using Biorender.com
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application scheme and at a higher frequency than FSCV to detect ambient levels of
transmitters. Currently this method is applicable to dopamine and serotonin detection. For
serotonin, the serotonin-specific waveform is applied at 100 Hz (vs. 10 Hz with FSCV) for
2 seconds to minimize adsorption to the electrode surface. Then a holding potential (0.2 V
for serotonin) is applied for 10s to allow a period for controlled adsorption of the ambient
serotonin in the extracellular space. The waveform is re-applied at 100 Hz for 18s to reduce
and oxidize the adsorbed serotonin. The peak on the voltammogram is converted to
concentration based on the individual calibration of each electrode after implantation into
the brain.
A depiction of the FSCAV waveform application scheme along with a
representative color plot for serotonin detection is shown in Figure 2.6. Using FSCAV,
we recorded basal values in these three regions 72.82 ± 3.21 nM in the CA2 region of the
hippocampus, 67.57 ± 3.42 nM in the mPFC and 39.71 ± 1.96 nM in the SNr. 143 We
attributed the lower serotonin level in the SNr to a much higher ratio of SERT mediated
uptake, strengthening our hypothesis of higher SERT density in the SNr. Thus, we
presented the power of FSCV as a chemical imaging probe that gives information about
local physiological architecture.
2.3 Conclusion
Modulators in the brain regulate the vast majority of neurochemical signaling
processes and are thus the targets of many psychoactive therapeutic compounds. The two
uptake processes for monoamine, Uptake 1 and 2, show that a more complex uptake profile
needs to be considered when studying and targeting monoamines. While much is known
about Uptake 1 processes, Uptake 2 mechanisms have been less studied. In general, it is
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difficult to study these mechanisms because analytical methods are limited in their spatial
and temporal resolving power to capture multiple uptake mechanisms in intact tissue. In
this chapter, we described different experimental approaches that have yielded important
information about Uptake 2 mechanisms and highlighted significant findings using each
method. It is clear from these works that Uptake 2 processes are critical to consider when
investigating brain monoamines.
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CHAPTER 3
MATHEMATICAL MODELS OF SEROTONIN, HISTAMINE, AND
DEPRESSION1

1Best,

J.,* Buchanan, A. M.,* Nijhout, F, Hashemi, P., & Reed, M. Excerpt form

Mathematical Models of Serotonin, Histamine, and Depression. IntechOpen. 2021 [Online
First] Reprinted with permission from IntechOpen.
33

3.0 Abstract
To better answer physiological questions of the brain, especially about mental
illness, it is critical to measure brain chemistry, specifically neurotransmitters. Measuring
neurochemistry is very challenging because neurotransmission is dynamic, and the brain
tissue is very delicate. The earliest brain analysis methods utilized brain biopsies that were
homogenized, separated and analyzed via HPLC.202 These methods are offline and give an
overview of whole tissue content, but not dynamic transmission. Microdialysis
revolutionized brain analysis by utilizing a probe implanted into the brain, perfused with
artificial cerebrospinal fluid (aCSF).103,

203

At the distal end of the probe is a semi -

permeable membrane with a cut-off point such that analytes of interest can diffuse into the
probe down a concentration gradient. The outcoming fluid, the dialysate, is collected and
analyzed with a secondary method such as HPLC. The time resolution of this method is
typically 10s of minutes. Niche electrochemical methods such as fast scan cyclic
voltammetry (FSCV) and fast scan-controlled adsorption voltammetry (FSCAV) can
measure the sub-second temporal profile neurotransmission,135, 204, 205 outlined below.
3.1 Fast-Scan Cyclic Voltammetry
Fast-Scan cyclic voltammetry (FSCV) is uniquely suited to measure
neurotransmission in vivo. Its fast temporal dynamics allows for neurochemical detection
on a sub-second timescale, approximately 1000 times faster than traditional cyclic
voltammetry. Furthermore, FSCV measurements are performed at microelectrodes,
typically carbon fiber microelectrodes (CFMEs). CFMEs have a small probe size
(diameter ~7 µm) and are biocompatible, creating minimal tissue damage and negligible
immune response.206, 207 Carbon electrodes also drive high sensitivity because their highly
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negative surface preconcentrates positively charged transmitters such as dopamine,
serotonin, norepinephrine and histamine. These transmitters are then readily oxidized at
the carbon surface, making it an ideal material for neurochemical measurements.
Traditionally, FSCV has been utilized to measure dopamine.107, 208, 209 However recent
advances have allowed for the detection of other neurotransmitters, such as serotonin and
histamine.125-127, 132
Serotonin is

measured using a CFME that

has

been modified by

electropolymerization of a thin, uniform layer of Nafion. Nafion, a cation exchange
polymer, increases the electrode sensitivity to serotonin while reducing the electrode
poisoning effects of serotonin metabolites.132 For in vivo experiments, this electrode is
placed in the brain region of interest, such as the hippocampus, prefrontal cortex, or
substantia nigra reticula (SNr). Because FSCV is a background subtracted technique,
serotonin is evoked using an electrical stimulation placed in the medial forebrain bundle
(MFB). Detection occurs by application of a waveform optimized for serotonin
measurements.125 This waveform has a resting potential of 0.2 V, scans up to 1.0 V, down
to -0.1 V, and then back to the resting potential of 0.2 V at a scan rate of 1000 Vs-1, applied
at a frequency of 10 Hz. The signal is presented in the form of cyclic voltammograms
(CVs) that qualify and quantify the substrate. Figure 3.1.A illustrates the FSCV
experiment.
Histamine is particularly difficult to detect in vivo using FSCV because it lacks a
clear, sharp oxidation peak. Samaranayake et. al developed a waveform that produces a
unique electrochemical histamine signal. It has a resting potential of -0.5 V, scans to -0.7
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V, up to 1.1 V, and then returns to the resting potential of -0.5 V at a scan rate of 600 Vs1.

This waveform simultaneously detects serotonin and histamine release in vivo.126, 127

Figure 3.1. Illustrative representation of an FSCV vs. FSCAV experiment described intext. A. shows the stimulation of the MFB to induce the release of serotonin in the CA2
and application of the serotonin waveform198 to detect the evoked change in serotonin
concentrations in the extracellular space over time. B. depicts the modified waveform
application for serotonin FSCAV201 that negates the need for electrical stimulation to detect
ambient concentrations of serotonin in the extracellular space each minute. This figure was
created with Biorender.com.
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3.2 Fast-Scan Controlled Adsorption Voltammetry
One limitation of FSCV is that because of the large capacitive current generated by
the fast scan rate, it is a background subtracted technique.210 This means that a change must
be evoked, often electrically or pharmacologically. To address this issue, Atcherly et al.
developed the method of fast-scan controlled adsorption voltammetry (FSCAV) to measure
ambient concentrations of dopamine.133, 134 This technique, illustrated in Figure 3.1.B, was
later adapted to measure serotonin.135 FSCAV occurs at the same microelectrodes as
FSCV. Serotonin FSCAV is performed in three steps: 1) The minimized adsorption step is
implemented by applying the waveform at 100 Hz for 2 seconds. 2) The potential is held
at +0.2 V for 10 s for a period of controlled adsorption. 3) The waveform is reapplied at
100 Hz for 18 seconds. The CVs taken in the 3rd step are subtracted from the 1st step and
thus serve as the ambient measurement.
3.4 The Chemical Basis of Neuro-inflammation
The vast majority of mental illnesses are associated with inflammation, especially
depression which is highly comorbid with inflammation.211 Increased levels of
proinflammatory cytokines in the interleukin-1 and tumor necrosis factor families are
linked to neuroinflammation

212, 213

across many different brain disorders. Chronic

neuroinflammatory states have been implicated in neurodegenerative disorders such as
Parkinson’s Disease

214, 215,

addition to depression

Alzheimer’s Disease,

211, 221

216-218

and multiple sclerosis,

219, 220

in

and bipolar disorder.222 While these associations are clear,

what is not known is how inflammation affects neurotransmission. This pitfall was
addressed by focusing on serotonin with FSCV and FSCAV. Serotonin is implicated in
depression because the vast majority of antidepressants target the serotonin system. 223
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Serotonin was first measured in vivo using FSCV in 1995 by Jackson et al. 125 The authors
detected serotonin in the rat striatum by forcing dopaminergic terminals to release
serotonin following loading with 5-Hydroxytryptophan and dopamine depletion with αmethyl-p-tyrosine. More recently, using the same waveform, the Hashemi lab measured
endogenous electrically evoked serotonin in the rat substantia nigra reticula (SNr). 132
Studies have since expanded to characterizing serotonin in different brain regions, studying
differences in male and female mice, looking at serotonin and histamine co-modulation
and observing the effects of inflammation on this co-modulation. The key findings using
serotonin electrochemistry are described below.
3.5 Serotonin Dynamics in Different Brain Regions
Serotonin release and reuptake in the rat SNr was first characterized following
electrical MFB stimulation.132 The SNr is of interest for serotonin detection as this area has
the most dense serotonergic innervation in the brain and thus serotonin is the primary
neurotransmitter released following electrical stimulation.224 The signals obtained in vivo
were pharmacologically verified using acute administration of the DAT inhibitor, GBR
12909, and the selective serotonin reuptake inhibitor (SSRI), citalopram. The signals did
not respond to DAT inhibition, however, following SERT inhibition, an increase in max
amplitude and a slowing of the reuptake was observed. Serotonin response to varying doses
of acute SSRI (1 mg kg-1, 10 mg kg-1, and 100 mg kg-1) was examined 225, with uptake t1/2
values increasing with dose concentration. However, no dose dependent trend was
observed for max amplitude values. Further analysis of serotonin reuptake mechanisms 226
were performed in collaboration with Best, Reed, and Nijhout through the development of
a Michaelis-Menten kinetic model as previously described in section three. The presented
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model establishes a two uptake mechanism for serotonin, a notion that was described back
in the 70s as Uptake 1 and 2.140 Uptake 1 refers to the high affinity, low efficiency system
characterized by the serotonin transporters (SERTs) and Uptake 2 is serotonin clearance
by the low affinity, high efficiency mechanism afforded by the dopamine, norepinephrine,

organic cation, and plasma membrane transporters.140, 183

Figure 3.2. The dark blue markers represent the average response before and after
pargyline (75 mg kg-1, intra-peritoneal (i.p.)) administration and the dark red markers
represent the average response before and after administration of GBR 12909 (15 mg kg-1,
i.p.). Drug injection time is denoted by the yellow bar at 0 min. Representative colorplots,
CVs, and concentration vs. time curves are inset (top, pargyline; bottom, GBR 12909,  =
predrug and  = postdrug). (Asterisks above blue markers indicate post hoc test: *p <
0.0001.) Reprinted with permission from the American Chemical Society.
While FSCV continues to provide insight into fast serotonin release and reuptake
dynamics, it is limited by its inability to measure steady-state or ambient concentrations.
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To address this limitation, fast scan controlled adsorption voltammetry (FSCAV) was
developed to detect both dopamine 134 and serotonin 135 in vivo. This technique (described
above) yields fast, selective, and sensitive absolute concentrations of serotonin. Using
FSCAV we reported serotonin concentrations of 64.9 ± 2.3 nM in the CA2.135 Figure 3.2,
shows ambient serotonin response to the monoamine oxidase B inhibitor, pargyline, in
comparison to the DAT inhibitor, GBR 12909. Ambient serotonin levels increase
following pargyline administration, but not following GBR administration, confirming that
the signal is serotonin.
FSCV measurements of serotonin were then expanded to the medial prefrontal
cortex (mPFC),227 another region associated with depression. Here, the Hashemi lab found
an interesting phenomenon whereby a double peak response was elicited in layers 1-3 of
the mPFC. Figure 3.3 shows examples of a single peak response as well as a variety of
double peak responses in this brain region. Interestingly each discrete peak had its own
specific reuptake profile, thus it was hypothesized that distinct axonal bundles in the MFB
terminate in layer-dependent mPFC domains with specific uptake transporters.
Finally in vivo serotonin signals were compared between the SNr, CA2 region of
the hippocampus, and the mPFC.228 It was determined that the different responses could be
modeled as a function of the percentage of Uptake 1/Uptake 2 transporters with the model
predicting the largest concentration of serotonin transporters in the SNr. The Hashemi lab
verified this notion with confocal microscopy and concluded that FSCV could be a
potentially useful tool for chemical imaging of local cytoarchitecture. Interestingly, and
counterintuitively, the SNr, with the highest density of serotonin terminals and axons, had
the lowest ambient levels of serotonin. This was determined to be because of the high
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affinity of SERTs (Uptake 1 transporters) in this region that serve to maintain steady state
levels lower than the other two regions with fewer SERTs.

Figure 3.3. Representation of single and double peaks reported by West et al. 2019 in the
mPFC. The average serotonin response is depicted in (A). Varying signals are shown in
(B) with a traditional single peak displayed in (i.) and five of the most common types of
double peaks shown in (ii.-vi.). The inset contains the CVs of both peaks. The first peak is
shown in blue and the second in red. Reprinted with permission from Elsevier.
3.6 Serotonin Dynamics Between the Sexes
The prevalence of depression differs between males and females, with women
being more likely to suffer from the disorder than men

229-231

. As such, it is important to

investigate neurochemical and pharmacodynamic disparities across the sexes. In the
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hippocampus, Saylor et al. observed no significant differences in the evoked serotonin
maximum amplitude or the t1/2 of clearance between male and female mice.232 Furthermore,
no differences were detected in the between the mean signal and the signal in different
stages of the female mouse estrous cycle. This suggests that there are no major sex
differences in the release or reuptake machinery in drug naive mice. Likewise, no
significant differences were detected across sexes in ambient levels of serotonin using
FSCAV. Differences in clinical efficacy have been observed following the administration
of SSRIs, a class of commonly prescribed antidepressants

233

. Following acute

administration of the SSRI, escitalopram, ambient serotonin concentrations increased
significantly, however no differences were seen between male and female mice.
Conversely, differences were observed in the evoked serotonin reuptake decay curve. At
all four doses given (1 mg kg-1, 3 mg kg-1, 10 mg kg-1, and 30 mg kg-1) the female mice
had a lower percent change in reuptake compared to the males. Saylor et al. concluded that
in female mice, compensatory mechanisms (likely via autoreceptors) exist to counteract
hormone mediated chemical fluxes that may affect serotonin.
3.7 Histaminergic Transmission and Modulation of Serotonin
As outlined above, inflammation (peripheral and brain) is becoming synonymous
with the pathophysiology of depression.211 The monoamine histamine is a major
inflammatory mediator in the body,234 associated with allergic reactions. However, less is
known about histamine’s role in the brain. While traditionally believed to be a
neuromodulator

in

the

CNS,

recent

studies

have

implicated

histamine

in

neuroinflammatory processes as well.235, 236 To study fast histaminergic dynamics, an
waveform was optimized to simultaneously detect histamine and serotonin in vivo 126, 127.
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Histamine oxidation was pharmacologically validated in the posterior hypothalamus
following application of tacrine, a histamine N-methyltransferase inhibitor, and
thioperamide, an H3 receptor antagonist. Acute tacrine administration slowed the reuptake
of histamine significantly, while thioperamide slowed the reuptake and increased the max
amplitude. Upon electrochemical release of histamine, a rapid inhibition of serotonin is

Figure 3.4. (A) In vivo [histamine] vs time plot and (B) simultaneous [serotonin] vs time
plot prior to (blue = histamine; red = serotonin) and after (green = histamine; orange =
serotonin) thioperamide (20 mg kg-1) administration. The model is shown by the dashed
lines. Reprinted with permission from Wiley.
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observed as shown in Figure 3.4. In this figure, release and reuptake of histamine (a) and
serotonin (b) are shown before and after thioperamide (H3 receptor antagonist)
administration. The responses can be modeled mathematically (dashed line). Notably, the
models include a function of histamine acting on inhibitory H3 receptors on serotonin
neurons.
3.8 Serotonin and Histamine in Inflammation Models
The inhibition of serotonin by histamine fueled our interest in the co-modulation of
these analytes in inflammation models. In recent work, the Hashemi lab found that upon
acute lipopolysaccaride (LPS) induced inflammation, ambient serotonin levels rapidly
decreased as a function of increased histamine. Escitalopram was much less capable of
increasing the serotonin levels under this inflammation state. It was determined that this
was because escitalopram (and other common antidepressants) inhibit histamine reuptake
serving to counteract the intended mode of action of the antidepressant. Only with the dual
strategy of targeting serotonin reuptake and histamine synthesis were we able to return the
serotonin to pre-inflammation control levels. The Hashemi lab is now actively studying
serotonin/histamine co-modulation in other inflammation/depression models in mice
including chronic stress and neurodegeneration.
3.9 Future Outlook
These in vivo studies have allowed the Hashemi lab to measure and compare and
contrast serotonin in different brain regions, to study serotonin dynamics in male and
female mice, to investigate serotonin and histamine co-modulation and to ask how this
modulation changes under inflammation. This program has provided invaluable
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information about the dynamics of these two modulators in health and pathophysiology in
mice.
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CHAPTER 4
A REAL TIME VOLTAMMETRIC STUDY OF SEROTONERGIC
SIGNALING IN A TOXICOLOGICAL MODEL OF PARKINSON’S
DISEASE1

1Buchanan,

A. M., Mena, S., Choukari, I., P., Hashemi, P. A Real Time Voltammetric

Study of Serotonergic Signaling in a Toxicological Model of Parkinson’s Disease. eLife.
In preparation.
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4.0 Abstract
The loss of midbrain dopaminergic neurons is well characterized in the context of
Parkinson’s Disease (PD), however, less is understood about serotonergic dysfunction.
Serotonin neurochemistry is linked to various aspects of the disease such as PD-associated
depression and levodopa induced dyskinesia (LID). As such, understanding serotonin
neurotransmission may help improve quality of life for PD patients. There are three key
prior hypotheses of the serotonergic underpinnings of PD. First that serotonin signalling is
impaired during PD, second that commonly prescribed SSRIs are less effective in PD
patients, and finally that LID is underscored by the serotonin system. Here we use fast
electrochemistry paired with mathematical modelling and machine learning to evaluate the
validity of these hypotheses. In an MPTP model of toxicological neurodegeneration, we
show that MPTP-treated mice exhibit lower concentrations of evoked and ambient
serotonin in the hippocampus as well as diminished serotonergic response to an SSRI. We
develop and train a novel neural network to predict the ratio of serotonin to dopamine in
electrochemical signals and following L-DOPA administration, we see a real-time shift
from evoked serotonin release to dopamine release. We hypothesize that this is due to an
increase in dopamine release from serotonergic neurons. Overall, these results verify key
hypotheses of the serotonin underpinnings of PD and open new avenues to think about
improving pharmacological treatments for the serotonin deficits of PD.
4.1 Introduction
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized
by a loss of midbrain dopaminergic neurons, leading to well characterized motor
symptoms. There are, however, a host of non-motor symptoms that are less well studied
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and are likely underpinned by other neurotransmitters, such as serotonin. Far less is
understood about dysfunction of the serotonergic system during the progression of this
disease. Serotonin is a monoamine neuromodulator that has long been associated with
major depressive disorder (MDD). Pharmaceuticals targeting the serotonergic system are
widely considered the first line of treatment in MDD.237 In recent years, however, serotonin
has also gained interest as a molecule of importance in PD. Although less consistent,
markers of serotonergic cell loss have been observed along with dopaminergic cell loss.36,
37, 65

Furthermore, the abnormal protein aggregates called Lewy bodies, are found in

serotonergic cell bodies in early stages of the disease, suggesting the serotonergic system
may be affected before the dopaminergic system.238 This along with serotonin’s role in
depression, aligns with reports showing that depressive symptoms often proceed motor
symptoms in PD by as much as 4-6 years.239
The most commonly prescribed antidepressants for both PD and non-PD patients
are selective serotonin reuptake inhibitors (SSRIs) as they are typically tolerated well by
the elderly and those with comorbidities.49 However, there are conflicting reports on
whether SSRIs are safe50-52 and effective53-56

in PD patients. Drugs targeting the

norepinephrine and dopaminergic systems have produced equally confounding results. 54,
55, 58, 59, 240

Levodopa (L-DOPA), the precursor for dopamine and the gold standard for

treatment of PD motor symptoms, has been shown to improve depression symptoms, 42
have no effect,60-62 or even to worsen symptoms in PD patients.63, 64 These discrepancies
are likely due to the fundamental difficulty in diagnosing human depression, such as such
as different metrics for assessing depression, lack of double-blind studies, or different
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experimental timelines. However, they highlight a need to better understand the underlying
neurochemical mechanisms of PD-associated depression.
One common side effect of chronic L-DOPA treatment is a motor complication
called levodopa induced dyskinesia (LID) that results in involuntary movements. Over
50% of patients treated with L-dopa for at least 5 years develop LID.75 In recent years,
serotonin has been implicated in the motor fluctuations associated with LID. Studies have
shown that serotonin neurons are can uptake L-DOPA,76, 77 and synthesize dopamine using
amino acid decarboxylase.78 The serotonergic neurons then have the ability to package and
theoretically release dopamine,79 but do not have the inhibitory dopamine autoreceptor
machinery to control this release, hence bursts of uncontrolled dopamine are thought to
lead to dyskinesia phenotype. This dopamine production may also occur at the expense of
serotonin production and release.80 A decline in serotonin release could explain worsening
of depression symptoms often seen following L-DOPA administration. Therefore, the
serotonergic system is of extreme interest in both PD-associated depression and LID. In
this study, we use novel techniques to explore the roles of serotonin in PD and test the
hypotheses recounted above. We find that animals administered MPTP have lower evoked
and ambient serotonin levels than controls and that SSRI administration to MPTP animals
is much less effective at increasing evoked serotonin release. We develop a procedure to
generate synthetic, labelled FSCV colorplots derived from in vivo acquisitions and use
them to train convolutional neural networks to predict a relative serotonin to dopamine
ratio of evoked release. We use this computational model to predict the changes of
serotonin and dopamine after L-DOPA administration for control and PD-induced mice.
We show the real-time displacement of serotonin by dopamine in the hippocampus during
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evoked release of LD-treated mice. Via this work we therefore experimentally verify key
serotonergic hypothesis of PD.
4.2 Materials and Methods
Chemicals and Reagents
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (16 or 18 mg kg-1, SigmaAldrich, St. Louis, MO, USA), escitalopram oxalate (10 mg kg-1, Sigma-Aldrich),
levodopa (50 mgkg-1 Sigma-Aldrich, St. Louis), benserazide (50 mg kg-1, Sigma-Aldrich,
St. Louis, MO, USA) were each dissolved individually in 0.9% sterile saline (Hospira,
Lake Forest, IL, USA) at a volume of 5.0 ml kg-1 animal weight and administered via
intraperitoneal (i.p.) injection. Urethane (Sigma Aldrich) was dissolved in sterile saline
(0.9%, Hospira) as a 25% w/v solution and administered at 7 µL kg-1 via i.p. injection. Four
point calibration solutions were prepared by dissolving serotonin (Sigma-Aldrich) into Tris
buffer to produce solutions with concentrations of 10, 25, 50, and 100 nM. Tris Buffer
consisted of 15 mM Tris Buffer consisted of 15 mM H2NC(CH2OH)2 HCl, 140 mM NaCl,
3.25 mM KCl, 1.2 mM CaCl2, 1.25 mM NaH2PO4 ·H2O, 1.2 mM MgCl2, and 2.0 mM
Na2SO4 (Sigma-Aldrich).
Electrode Fabrication
Carbon fiber microelectrodes were fabricated by aspirating a carbon fiber
(Goodfellow Corporation, Coraopolis, PA, United States) into a glass capillary (0.4 mm
internal diameter, 0.6 mm outer diameter, AM Systems, Carlsborg, WA, United States).
Electrodes were pulled to a fine tip using a vertical pipette puller (Narishige Group, Tokyo,
Japan), creating a carbon-glass seal. The exposed carbon fiber was then cut to 150 µm
under a light microscope. Nafion (L-Q-1105, Ion Power, New Castle, DE, USA) was
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electroplated onto the electrode surface by applying a constant potential (~1 V) for 30 s.
The electrode was then dried for 10 min at 70° C.
Animals and Surgical Procedure
All animal procedures and protocols were performed in accordance with
regulations of the Institutional Animal Care and Use Committee (IACUC) at the University
of South Carolina, which operates with accreditation from the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC). Male and female C57BL/6J
mice at 10-14 weeks of age were group housed on a 12 h light dark cycle with ad libitum
access to food and water. At 10-11 weeks of age, mice underwent an acute MPTP injection
paradigm (4 doses every 2 h, i.p.).99 Mice were injected with MPTP hydrochloride, while
control mice were administered an equal volume of saline. Male mice received a dose of
18 mg kg-1 MPTP and female mice received a dose of 16 mg kg-1 MPTP, a dose more
easily tolerated by the smaller female mice. The lesions were allowed to stabilize 7 days
before surgeries were performed.
Following the administration of urethane anesthesia via i.p. injection, stereotaxic
surgery was performed with all coordinates taken in reference to bregma. A CFM was
lowered into the CA2 region of the hippocampus (AP: -2.91, ML: +3.35, DV: -2.5 to 3.2)
and compared to a pseudo Ag/AgCl reference electrode placed in the contralateral
hemisphere. The Ag/AgCl reference was created by chloridizing a polished silver wire in
1 M HCl for 15 s at 5 V. A stimulating electrode (insulated stainless steel, diameter: 0.2
mm, untwisted, Plastics One, Roanoke, VA, United States) was placed into the medial
forebrain bundle (AP: -1.58, ML: +1.00, DV: -4.8). A thermal heating pad (Braintree
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Scientific, Braintree, MA, USA) was used to maintain mouse body temperature for the
duration of the experiment.
Data Collection and Analysis
Fast scan cyclic voltammetry (FSCV) was performed on anesthetized mice to
measure phasic serotonin release and reuptake as previously described. (Hashemi, 2009;
Saylor, 2019) All measurements were collected using a Dagan potentiostat (Dagan
Corporation, Minneapolis, NM), custom built hardware interfaced with PCIe 6431 and PCI
6221 DAC/ADC cards (National Instruments, Austin, TX), and a Pine Research headstage
(Pine Research Instruments, Durham, NC). WCCV 3.06 software (Knowmad
Technologies LLC, Tucson, AZ) was used to apply the serotonin waveform (0.2 V to 1.0
V to -0.1 V to 0.2 V) at a scan rate of 1000 V/s. The waveform was cycled at a frequency
of 60 Hz for 10 min, then at 10 Hz for 10 min prior to data acquisition. A biphasic electrical
stimulation (60 Hz, 360 µA, 2 ms in width) was applied for 2 s through a linear constant
current stimulus isolator (NL800A Neurolog, Medical Systems Corp, Great Neck, NY) to
evoke serotonin release.
Data were collected and filtered using WCCV software (zero phase, Butterworth,
3 kHz low pass filter). Four control measurements, taken every 10 min, were collected and
averaged. Then either escitalopram (10 mg kg-1) or a combination of L-DOPA (50 mg kg1)

and benserazide (50 mg kg-1) were administered. Measurements were taken at the 0 min,

5 min, and 10 min time points and then once every additional 10 minutes for 2 hrs following
drug administration. The obtained currents were converted to concentration using a
previously reported calibration factor (11 µM nA-1).108 Maximum amplitude of evoked
release was measured for each individual repetition using custom-designed peak finding
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algorithms. Area under the curve was measured using the Simpson’s rule. Clearance rate
(t1/2) of the decay trace was measured by fitting an exponential decay curve after the
maximum amplitude of the release.241 A previously described Michaelis-Menten model
with two reuptake processes199 was fitted to the average FSCV trace of each group.
Fast scan controlled adsorption voltammetry (FSCAV) was utilized to measure the
ambient concentrations of serotonin135 in vivo using the same hardware as FSCV. Control
evoked serotonin measurements were collected prior to switching to basal collection. For
FSCAV collection, the serotonin waveform was applied at a frequency of 100 Hz for 2 s
to minimize adsorption to the electrode surface. This was followed by a period of controlled
adsorption where the electrode is held at a constant potential (0.2 V) for a period of 10 s.
Finally, the waveform was reapplied at 100 Hz and the first CV characteristic of serotonin
was selected. Control measurements were collected once a minute for 30 minutes.
Following control measurements, saline was administered i.p. (5.0 mg kg-1) and files were
taken for an additional 30 minutes. Animals were then administered escitalopram (10 mg
kg-1, i.p.) and 60 files were collected. The peak observed between 0.4 V and 0.8 V was
integrated to obtain a charge (pC) and following removal from the brain, a post calibration
of each electrode was used to determine concentration (solutions of 10, 25, 50, and 100 nM
serotonin in Tris buffer).
Behavioral Analysis
Open Field Test
Open Field Test (OFT) was used as a measure of locomotor activity in mice
administered either saline or MPTP. Prior to drug administration, mice were habituated to
the open field apparatus (plexiglass, 35 x 35 x 35 cm) for 10 minutes over 2 days. Activity
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of each mouse was then tracked and quantified (Noldus Ethovision) over a 20 minute
period on the third day. Seven days following administration of either saline or MPTP,
animals were administered either a combination of L-DOPA (6.25 mg kg-1, i.p) and
benserazide (10 mg mg kg-1, i.p) or an equal volume of saline for a total of 3 days. Animals
then underwent open field testing again for a 20 minute period and total distance travelled
was measured.
Elevated Zero Maze
Seven days following the administration of either saline or MPTP the elevated zero
maze (EZM) was performed as previously described as a measure of anxiety-like
behavior.242 At the onset of each trial, the mouse was placed in one of the closed arms of
the apparatus (Maze Engineers, Boston, MA, USA) and allowed to explore for 5 minutes.
This was repeated for each saline and MPTP mouse. Anxiety-like behavior is measured by
the percentage of time spent in the open arms.243 The number of entries into the closed
arms indicates levels of overall activity.244
Tail Suspension Test
The tail suspension test (TST) was conducted as a method for establishing
depressive-like behavior in control mice given saline compared to MPTP mice.245 Trials
were performed seven days following the administration of saline or MPTP. Each mouse
was attached to the rod on the apparatus (Maze Engineers, Boston, MA, USA) by tape for
a duration of 6 minutes. A small, flexible plastic cone was placed at the base of each
mouse’s tail to prevent climbing behavior. Increased immobility time was measured as an
indicator of behavioral despair.
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Statistical Analyses
Statistical significance is defined as p < 0.05. All statistical tests are performed
using Matlab 2020b and GraphPad Prism. Sample distributions are described as mean ±
SEM if not stated otherwise. Differences in maximum amplitude, clearance rate and AUC
between groups were tested for significance using analysis of variance (ANOVA) and
Tukey-Krammer post-hoc multiple comparisons. A complete description of the statistical
results can be found in the Supplementary Information.
Computational Strategies
Data Augmentation
Data augmentation of in vivo acquisitions was performed to generate synthetic data
as a combination of two random control acquisitions (colorplots) known to be
representative of a serotonin evoked release (drawn from the CA2 region of the
hippocampus) and dopamine evoked release (drawn from the striatum). The operation to
obtain the synthetic colorplots is expressed in eq.2

Xk = rkA + (1-rk)B

(2)

where Xkis the new synthetic colorplot, rkis the randomised ratio from 0 to 1, and A and
B are the serotonin and dopamine control colorplots from their respective regions of the
brain, respectively. All the colorplots used to generate synthetic data are standardised to
have a mean of zero and standard deviation of unity to prevent artifacts due to differences
in current amplitude of the colorplots. Five thousand colorplots were generated per animal
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with randomised ratio, serotonin and dopamine acquisitions to be used as training and
validation set for the neural network models (vide infra).
Artificial Neural Networks
Artificial neural networks (ANN) are designed, trained and deployed using
Tensorflow and Keras in Python 3.9.2. The ANN were designed to function as regression
models; the final layer of the ANN model consists of a unity node which predicts a relative
ratio of serotonin to dopamine from the two-dimensional colorplot. The predicted ratio of
serotonin to dopamine is relative to dopamine measurements in the striatum of rodents
(assumed to have a ratio of zero) and serotonin measurements in the CA2 region of the
hippocampus of rodents (assumed to have a ratio of one). ANN trained in this work
consisted of a convolutional neural network of 11 layers: two convolution layers, one max
pooling layer, four leaky rectified linear unit (RELU) layers, a flatten layer after the set of
convolution layers and three deeply connected (dense) layers. All layers were integrated in
a sequential model. The first hidden layer consisted of a convolution layer (275 features),
which computes the Hadamard product of a kernel of 3-by-3 with each of the input values
of the colorplot.246 This is followed by a scalar exponential linear unit (SELU) activation,
which follows the mathematical function shown in eq.2.247
f(x) =sx, sx

(3)

where s and α are predefined constants (s = 1.051 and α = 1.673). Data dimensionality and
overfitting were reduced with the use of a succeeding max pooling layer (i.e.
downsampling the input along its spatial dimensions by taking the maximum value over an
input window of size 3-by-3). A third layer with leaky RELU was then applied following
the mathematical expression on eq.4:
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f(x) =x

(4)

where is set to 0.1. The fourth and fifth layers consisted of a consecutive convolutional
layer (100 features) and leaky RELU activation function (α = 0.1). The structure of the
CNN was then flattened and a set of dense and leaky RELU were applied to the onedimensional input stream. The CNN finishes with a unity output node which predicts the
relative ratio of serotonin to dopamine. Figure XA shows the schematic structure of the
convolutional neural network.
The model was trained with 5000 synthetic control colorplots and ratios per animal
acquisition (vide supra). Training and test splits were set to a 4:1 ratio. Training batches
were set to 30 shuffled colorplots and train and validation splits were set as 4:1 ratio with
4 steps per iteration and 5 validation steps. The model was trained using the Adam
optimizer248 with a learning rate of 0.0001 and mean absolute error as the loss function.
The root mean square error (RMSE) between predicted and true ratios was used to assess
the predictive power of the neural network. Additionally, 500 iterations were used as higher
values did not improve the predictive error of the regression. Similarly, fewer iterations
were found to reduce the performance. After training, unseen acquisitions after LD
administration were used to predict the change of relative ratio of serotonin and dopamine.
4.3 Results and Discussion
4.3.1 Behavioral Analysis
Parkinson’s patients often exhibit movement changes such as bradykinesia. This
necessitates that locomotor changes are evaluated in animals receiving MPTP. To evaluate
locomotion in mice, open field analysis was used (Figure 4.1). No difference was observed
in animals administered MPTP (total locomotion = 5034 ± 153 cm) compared to animals
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receiving saline (total locomotion = 5469 ± 467 cm). The effects of MPTP administration
on locomotion are notoriously unreliable with studies showing decreased locomotion,249251

no change,252, 253 and hyperlocomotion.254, 255 These differences in locomotor behavior

may be attributed to differences in injection paradigms, mouse strains, age of animals, or a
variety of other differences across experiments. However, the lack of change in locomotion
that we see has been observed previously with the same strain and MPTP injection

Figure 4.1: Comparison of total distance travelled in OFT between mice administered
either saline or MPTP. Seven days following administration of MPTP, mice were then
administered either saline or a combination of L-DOPA + benserazide. No difference in
locomotion between saline/saline (n = 10) and MPTP/saline animals (n = 12) or MPTP
animals that received saline or L-DOPA + benserazide (n = 10). Locomotion increased
observed in mice administered MPTP/L-DOPA + benserazide compared to Saline/Saline
animals (student’s t-test, p < 0.001).
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paradigm used in these experiments.252 Interestingly, mice administered L-DOPA (total
locomotion = 6491 ± 333 cm) exhibited hyperlocomotion compared to the saline animals
(student’s t-test, p < 0.001). This may be due to the administration of L-DOPA shortly
before the behavioral trials. Sgroi et al. show that rodents display increased locomotor
activity following L-DOPA injection.256 This is a period deemed the ON phase of L-DOPA
treatment.
Tail suspension test (TST) was used to evaluate depressive-like symptoms245 while
elevated zero maze (EZM) was used to assess anxiety-like behaviors.242 Following MPTP
administration, mice exhibited a greater immobility time in the TST (Figure 4.2.A) than
saline control animals (MPTP: 151 ± 41 s, saline: 119 ± 27 s, student’s t-test, p <0.05). As
there was no significant difference in locomotor activity in the OFT, this increase in
immobility time is attributed to behavioral despair and not motor deficits resulting from
the MPTP lesion. Zhang et al. shows that mice administered MPTP exhibit greater

Figure 4.2: (A) Increase in total time immobilized in TST for MPTP (n = 16) compared to
saline mice (n = 11) (p < 0.05). (B) No statistical difference in time spent in open arms in
the EZM between MPTP (n = 15) and saline mice (n = 10). (C) No statistical difference in
closed area entries between MPTP and saline mice in the EZM.
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immobility times 14 and 21 days following MPTP administration.257 While they do not see
differences 7 days post MPTP administration, Zhang et al. uses a semi-chronic injection
schedule where they inject MPTP once a day for 5 consecutive days (25 mg kg -1). This is
a both a lower cumulative dose as well as a much less aggressive injection paradigm than
the one used in this study. It is reasonable therefore that using our injection paradigm, we
observe behavioral deficits at an earlier time point.
Saline (28 ± 8%) and MPTP (33 ± 11%) mice spend a similar percentage of time
in the open arms compared to the closed arms (student’s t-test, p = 0.23)(Figure 4.2.B). A
higher amount of time spent in the open arms is indicative of less anxiolytic behavior.
Furthermore, both saline (4.3 ± 2.1 entries) and MPTP (5.1 ± 3.9 entries, student’s t-test, p
= 0.54) mice had a comparable number of entries into the closed arm (Figure 4.2.C),
showing that both groups have similar overall activity levels. MPTP animals have neither
an increased anxiolytic behavior or decreased activity compared to control animals.

4.3.2 Evoked Serotonin is Diminished in MPTP Mice
It has long been known that PD patients exhibit abnormalities in neurotransmitter
systems other than dopamine.258, 259 Post-mortem studies show PD patients have lower
concentrations of serotonin in the hippocampus both in groups receiving L-DOPA and
those that have discontinued use.258 However, one major limitation in the study of PD, is
finding a translatable model from human to animal. The MPTP model of parkinsonism is
one of the more common models for dopaminergic lesioning, however, there are many
different injection regimens used. Pain et al compared dopamine and serotonin
concentrations following acute, subacute, and chronic MPTP paradigms in multiple brain
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Figure 4.3 (A) Representative colorplot depicting serotonin oxidation (blue dot) in a mouse
administered MPTP. Vertical line shows the CV overlaid in the right-hand corner.
Horizontal line shows the concentration vs time (IT) curves presented in B-C. (B) IT curve
comparing male mice administered saline vehicle (blue trace, n = 9) vs female mice
administered saline (pink trace, n = 10). (C) IT curve comparing male mice administered
MPTP (blue trace, n = 13) vs female mice administered MPTP (pink trace, n = 9). (D)
Comparison of max amplitudes of FSCV curves presented in B-C. Saline animals evoke
significantly higher serotonin than MPTP mice (p < 0.05). (E) Comparison of serotonin
reuptake decay curves for animals shown in B-D (no significance).
regions (including the striatum and hippocampus).260 In this study hippocampal serotonin
concentrations were lower in the acute and subacute injection paradigms but not the chronic
paradigms using HPLC. As we are interested in the effects of MPTP on serotonin
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transmission, we thus used the acute MPTP injection protocol throughout this study.98, 99,
101, 260

FSCV allows us to study sub second serotonin dynamics. Here we use it to evaluate
the release and reuptake of mice receiving acute doses of MPTP compared to those that
receive saline. Figure 4.3A shows a representative FSCV colorplot for serotonin oxidation
in a mouse administered MPTP. The measurements are visualized as a two-dimensional
plot (voltage vs time) with the third dimension (current) in false color. The serotonin
oxidation is represented by the blue-green dot. The cyclic voltammogram (CV) can be
extracted by taking a vertical section (vertical dotted line) of the colorplot and is shown in
the upper right-hand corner of the plot. Likewise, the current vs time curve can be obtained
by taking a horizontal section (horizontal dotted line) that depicts how the analyte is
changing over time (i.e. Figures 4.3.B-C). We used FSCV to measure the evoked serotonin
response in the CA2 region of the hippocampus in mice administered MPTP as compared
to ones receiving saline and used a two-way ANOVA analysis to compare the effects of
sex and drug administration (Figures 4.3.B-C).
As depicted in Figure 4.3.E, Stimulated serotonin max amplitudes of MPTP
animals were significantly lower than that of the saline controls (Student’s t-test, Ampmax
= 27.7 ± 2.0 vs. 40.2 ± 5.2 nM, p = 0.0149). There was no significant difference in reuptake
between MPTP mice and saline controls (Figure 4.3.F)(Student’s t-test ,t1/2= 1.79 ± 0.19
vs. 2.27 ± 0.33 s, p = 0.1851). Additionally, we performed Michaelis Menten modeling to
further evaluate in vivo serotonin kinetics.199, 232 Serotonin kinetics incorporate terms from
two different uptake mechanisms. Uptake 1 is a high affinity, low efficiency process that
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consists of uptake from the serotonin transporter (SERT). Uptake 2 is a low affinity, high
efficiency process via uptake from transporters non-specific to serotonin such as dopamine
transporters (DATs), norepinephrine transporters (NETs), organic cation transporters
(OCTs) and plasma membrane transporters (PMATs). The kinetic model also accounts for
the strength of the autoreceptor effect A(t) and firing rate due to the strength of the input
R(t). There is little difference in the transporter uptake mechanisms between MPTP and
saline mice (MPTP: Vmax1 = 15.8 nM s-1, km1 = 2.3 nM, Vmax2 = 780 nM s-1, km2 = 170 nM;
saline: Vmax1 = 14.7 nM s-1, km1 1.3 nM, Vmax2 = 780 nM s-1, km2 = 170 nM). However, the
MPTP mice (R(t) = 24.2 nM s-1) exhibit an ~30% lower release rate than that of the saline
mice (R(t) = 35.2 nM s-1), suggesting a decreased neuronal input strength in MPTP
animals.143
Because of the nature of FSCV experiments, animal surgeries are performed over
a range of days and with animals of mixed sexes. No FSCV surgeries were performed for
the first week following acute MPTP injections to allow for stabilization of the lesions. A
two-way ANOVA analysis with effects of sex of mouse (Figure 4.3.D-E) and time after
MPTP injection (7 to 13 days or 14 to 21 days) allowed to discard a significant effect of
time after MPTP injection in the maximum amplitude of release of the evoked traces (twoway ANOVA, F = 0.17, p = 0.6865) and calculated clearance of the reuptake curve (twoway ANOVA, F = 0.55, p = 0.4677). We show no statistical difference in evoked serotonin
7 to 13 and 14 to 21 days after MPTP administration. This is consistent with studies
showing a prolonged decrease in serotonin concentration in the striatum, cortex and
amygdala 7 and 30 days following MPTP administration.101
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It has been suggested that the acute MPTP model of parkinsonism may mimic early
stages of PD.260 Early serotonergic involvement has been demonstrated in the disease
making the acute model of particular interest.38, 261, 262 Furthermore, a loss of serotonergic
neurons in the median raphe nucleus has been observed in PD patients. 262 These neurons
have projections to the hippocampus17, 263, 264 and may be responsible for the decreased
serotonergic input we see in MPTP mice. Additionally, we have shown in previous studies
that evoked stimulation of histamine causes a rapid inhibition of serotonin release.126, 127
PD patients have been shown to have increased brain histamine levels and show alterations
in expression of histamine receptor density.265, 266 It is unknown whether hippocampal
histamine levels are affected in MPTP animals.
4.3.3 No Difference in Evoked Serotonin Release in Male and Female MPTP Mice
Clinical depression is reportedly twice as prevalent in females compared to
males,229, 230 making an assessment of sex differences highly important for studies that have
a context of depression. In Figure 4.3.B-C, we compare the current vs time curves for male
and female mice that have been administered saline and MPTP respectively. A two-way
ANOVA analysis (vide supra) was used to test the effect of the sex of mouse in the
parameters of the evoked traces. No significant effect of sex of mice is found in the
maximum amplitude of release of the evoked traces (two-way ANOVA, F = 0.22, p =
0.639; Male: Ampmax = 25.5 ± 2.1 nM, Female: Ampmax = 31.1 ± 3.8 nM) or calculated
clearance rate of the reuptake curve (two-way ANOVA, F = 0.34, p = 0.5617; Male:
t1/2=1.69 ± 0.21 s, Female: t1/2=2.10 ± 0.35 s).
Sex differences are of import in PD studies as men have a 2-fold higher incidence
of PD compared to women.267 This has been attributed to estrogen associated
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neuroprotective effects268,

269

and is consistent in MPTP induced parkinsonism as

endogenously applied estrogen has been shown to have neuroprotective effects in this
model.270, 271 In this study we did not investigate the female estrous cycle, however, while
we note high estrogen stages (estrus and proestrus) may be more resistant to dopaminergic
lesioning, we see no overall difference serotonergic signaling in male and female mice.
These findings are comparable to previous studies we have published showing no sex
differences in release or reuptake in healthy mice.232 While we do not present a comparison
of data broken down into estrous cycle phases here, previous experiments show no
difference in max amplitude or t1/2 during the different stages.232
4.3.4 Escitalopram Administration has Less Effect on Serotonin in MPTP-Treated Mice
Here we evaluate the evoked release of serotonin in MPTP-treated mice vs. mice
receiving saline before and after acute administration of the SSRI, escitalopram (escit) (10
mg kg-1). Representative colorplots for serotonin oxidation in the CA2 region of the
hippocampus in MPTP animals are presented in Figures 4.4.A and 4.4.B. Figure 4.4.A
shows serotonin oxidation prior to drug administration, while Figure 4.4.B displays
oxidation 60 minutes following escit administration. A visible slowing of the reuptake can
be seen in Figure 4.4.B. The CV is used to identify serotonin and can be extracted at the
time indicated by the vertical dashed line. The concentration vs time curve is extracted
from the horizontal dashed line and represented as in Figures 4.4.C and 4.4.D. Following
administration of escit, we typically see two phenomena in the hippocampus. The first is a
drastic slowing of serotonin reuptake and the second is a large increase in serotonin
released. We see both of these characteristics in Figure 4.4.C for animals receiving saline
following escit administration. The maximum release amplitude in these animals increases
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from 35.6 ± 4.3 nM prior to escit administration to 75.2 ± 14.3 nM after escit is applied
(post-hoc test, p= 0.0162) (Figure 4.4.E). T1/2 values analyzing the reuptake decay curve
are presented in Figure 4.4.F. For saline animals, as the reuptake slows following escit
administration, the t1/2 values increase from 2.47 ± 0.82 seconds in control files to 26.70 ±
3.89 seconds 60 minutes following drug administration. (post-hoc test, p < 0.0001). The
current vs time traces for mice administered MPTP are shown in Figure 4.4.D both before
and after escit administration. MPTP mice exhibit the characteristic slowed reuptake
following escit (Figure 4.4.F)(post-hoc test, t1/2 = 1.24 ± 0.31 vs. 17.92 ± 5.96 s, p =
0.0001), however the increase in max amplitude(Figure 4.4.E) is less drastic than that of
the saline animals (post-hoc test, Ampmax= 23.6 ± 3.4 vs. 37.5 ± 7.3 nM, p = 0.9958). We
give more context on this below with modelling the release and reuptake curve.
We evaluate Michaelis-Menten kinetics for average stimulated responses of MPTPadministered and saline-administered mice before and after escit with a previously
developed mathematical model. We find a clear decrease in the maximum vesicular release
rate in MPTP-treated mice before and after escit injection (approximately ~28% and ~33%
lower, respectively). Importantly, in both MPTP and saline mice, following escit
administration, Vmax reduces by ~60% and ~70%, respectively, while Km increases by
1300% and 3000%, respectively. When the Vmax of the serotonin transporters decreases
and Km increases (upon uptake inhibition), one would expect the FSCV release signal to
increase because serotonin is not being as quickly re-uptaken (and not because more
serotonin is released). This is the case in Figure. 4.4.C and D. Indeed our modelling shows
that the maximum vesicular release after escit administration does not significantly change
with respect to the respective control state (groups are different from each other, as above)
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(~13% and ~8% lower for MPTP and saline mice, respectively). This validates that, as
expected, escit acts by reducing the reuptake affinity and capacity of the serotonin
transporters and not on the vesicular release of the neurotransmitter. An interesting point
here is that, despite escit dramatically increasing the K m of SERTs to a higher extent in
MPTP mice, the serotonin release is lower in MPTP-mice compared to controls. This is in
line with generally less serotonin release in MPTP-treated mice.
4.3.5 MPTP Mice Exhibit Lower Basal Serotonin Levels than Control Animals
Because FSCV is background subtracted, responses using this technique must be
evoked so that a change is measurable. Notably, the large electrical stimulations used in
FSCV, may result in aphysiological release of serotonin that is much higher than would be
released naturally. Therefore, to measure ambient concentrations of serotonin we used a
modification of FSCV called fast scan controlled adsorption voltammetry (FSCAV). 201
Using FSCAV, MPTP animals exhibit a lower ambient serotonin concentration (11.6 ± 0.6
nM) compared to animals receiving saline (32.7 ± 1.9 nM) prior to escit administration (10
mg kg-1, i.p) (post-hoc test, p < 0.0001). In both animal groups, serotonin concentrations
are raised significantly 60 minutes following escit administration (post-hoc tests, Control:
32.7 ± 1.9 vs. 65.34 ± 19.61 nM, p = 0.0269; MPTP: 11.6 ± 0.6 vs. 26.69 ± 10.14 nM p =
0.0243). However, because of the lower overall ambient concentrations, MPTP
concentrations do not reach the same final serotonin concentrations as saline animals from
the 55-60 minute timepoints (MPTP: 28.3 ± 4.7 nM; Saline: 66.8 ± 8.4 nM; Student’s ttest, p < 0.001).
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Figure 4.4. (A) Representative colorplot depicting serotonin oxidation (blue dot) before
escit administration in a mouse administered MPTP. Vertical line shows the CV overlaid
in the right hand corner. Horizontal line shows the concentration vs time (IT) curves
presented in C and D. (B) Representative colorplot depicting serotonin oxidation (blue dot)
after escit (10 mg kg-1) administration in a mouse administered MPTP. Vertical line shows
the CV overlaid in the right hand corner. Horizontal line shows the concentration vs time
(IT) curves as presented in C and D. (C) IT curve comparing mice administered saline
before (light blue) and after (dark blue) escit (10 mg kg-1) administration (n = 5). (D) IT
curve comparing mice administered MPTP before (light red) and after (dark red) escit (10
mg kg-1) administration (n = 5). (E) Comparison of max amplitudes of FSCV curves
presented in C and D. Saline animals evoke significantly higher serotonin than MPTP mice
before (post-hoc test, Ampmax= 35.21 ± 2.17 vs. 23.56 ± 1.70, p = 0.0336) and after escit
(post-hoc test, Ampmax= 75.22 ± 14.25 vs. 37.46 ± 7.32, p = 0.0095). (F) Comparison of
serotonin reuptake decay curves for animals shown in C and D. No statistical significance
was found in the clearance rate of evoked serotonin between saline and MPTPadministered animals before (post-hoc test, t1/2= 2.67 ± 0.44 vs. 1.24 ± 0.15, p = 1.000) or
after escit administration (post-hoc test, t1/2= 26.70 ± 3.89 vs. 17.92 ± 5.96, p = 7691). See
the Supporting Information for all statistical comparisons. (G) Ambient concentrations of
serotonin collected using FSCAV before and after escit administration for MPTP (red dots,
n = 5) and saline (blue dots, n = 5) animals.
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It has been widely reported that PD patients experience progressive, variable
serotoninergic loss.65, 66, 272. Decreased serotonin concentrations have also been shown in
the acute MPTP model of parkinsonism.260 The dopaminergic and serotonergic
systems are widely accepted to interact and regulate each other. Serotonin receptors have
been shown to modulate dopamine activity across multiple brain regions, 273 while
dopamine receptors have been shown to indirectly mediate serotonin release in the
hippocampus.274 It is possible that dopaminergic alterations affect ambient serotonin
release. Additionally, MPTP neurodegeneration has been shown to increase
neuroinflammation through pro-inflammatory cytokines in multiple brain regions.275 We
and others have shown that serotonin concentrations are negatively impacted in
neuroinflammatory states.276-278 In a neuroinflammatory state caused by acute
lipopolysaccharide administration, Hersey et al. show that inhibition of the proinflammatory neuromodulator, histamine, restore serotonin levels following escit
administration.276 As PD patients have been reported to have increased histamine
concentrations,265

we suggest the possibility that increased histamine levels are

suppressing the ambient serotonin concentration. This is the focus of our future work.
4.3.6 Neural Networks as Predictive Models of In Vivo Acquisitions
We next wanted to ask about the effects of L-DOPA administration on the serotonin
signal. L-DOPA, a dopamine precursor, is the gold standard in treatment for motor
symptoms of PD. However, chronic treatment has presented with unintended side effects.
For example, studies have shown a worsening of depression symptoms in PD patients
following L-DOPA administration.63, 64 Furthermore, serotonergic dysfunction has been
linked to LIDs in the striatum.70-73 It is theorized that following L-DOPA administration,
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serotonin neurons have the ability to uptake L-DOPA,76, 77 synthesize dopamine,78 and
potentially release it into the extracellular space at the expense of serotonin release. 79, 80
This unregulated release of dopamine from serotonin terminals is thought to be responsible
for the disjointed movements observed following L-DOPA treatment.69,
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Thus, we

suspected that dopamine might be co-released after this treatment, which creates an
analytical quandary. Dopamine and serotonin differ in their physiological function and the
ability to co-detect both analytes from a single FSCV acquisition has yet not been fully
developed. Despite their physiological differences, both molecules are involved in an
electrode transfer reaction at an optimal potential between 0.7 and 0.8 V on the “Jackson”
waveform. Commonly, the dopamine faradaic peak is shifted closer to 0.8 V, and the
electrode sensitivity is reduced, since the waveform was originally developed to detect
serotonin.132 Because of the similarities between the faradaic peaks, conventional in vitro
calibration techniques (e.g., linear regression and partial least squares regression) are not
able to distinguish and quantify between both analytes. Additionally, due to mass transport
and matrix differences between the in vitro and the in vivo environment, faradaic peaks are
commonly shifted, and the overall shape of the CV differs between both media for both
analytes. Here we propose an alternative to conventional in vitro calibrations which
consists on the use of reference in vivo signals of the analytes.
To pharmacologically confirm dopamine, we drew evoked signals from the
striatum of mice, a brain region strongly innervated by dopaminergic neurons, and after
pharmacological treatment with DAT inhibitor, GBR-12909, we certified that the analyte
reacting was mostly dopamine (Figure 4.5). Acquisitions from the CA2 region of the
hippocampus are also expected to be majorly evoked release of serotonin. From these

70

Figure 4.5: (A) Representative control colorpot and corresponding CV for measurements
taken in the striatum using the serotonin waveform. The serotonin peak is at ~0.8 V. (B)
Signal is unresponsive to administration of the SSRI, escitalopram, showing that signal is
not serotonin. (C) Signal is responsive to administration of the DAT inhibitor, GBR-12902
showing that signal is in part dopamine.

original acquisitions, data augmentation was applied to generate labelled synthetic in vivo
colorplots (a randomised relative ratio of serotonin from the CA2 region to dopamine from
the striatum) using mathematical expression shown in eq.1.
A convolutional neural network was then designed and trained using the synthetic
signals to predict the relative ratio from the whole colorplot. The structure of the neural
network was optimized to improve the performance of the CNN in the prediction of the
ratio from unseen test data. A low training and validation loss, as well as predictive error
(RMSE) was achieved using 500 epochs (see Supporting Information). After the training,
the neural network was used to predict the relative ratio of serotonin to dopamine. Figure
4.6.A shows the schematic of the final CNN model after optimization. Briefly, the function
of the model is to select features from the colorplot (via convolution) that contribute to
determine whether the acquisition resembles a serotonin release (such as those found in the
CA2 region of the hippocampus) or a dopamine release (such as those found in the
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striatum).The features of the colorplot deemed to be the most important in the
determination between serotonin and dopamine are shown in Figure 4.6.B.

Figure 4.6 (A) Convolutional neural network architecture schematic. (B) Heat map
showing important aspects of the colorplot used in the convolutional neural network. Most
important areas are shown in yellow.
4.3.7 L-DOPA Administration Replaces Vesicular Release of Serotonin for Dopamine
in the Hippocampus
Here we used our convolutional neural network to identify changes from a
serotonin-rich release to a dopamine-rich release from color plots (vide supra). We then
used the model to obtain a prediction of a relative ratio of serotonin to dopamine in the
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CA2 region of the hippocampus after levodopa administration for the different mice
cohorts. The experiment was to measure evoked serotonin release in the CA2 region of the
hippocampus with FSCV, then apply pharmacological challenge, and measure evoked

Figure 4.7. (A) Representative colorplot depicting serotonin oxidation (blue dot) before
L-DOPA administration in a mouse administered saline. Horizontal line shows the shift in
the center of the serotonin oxidation. (B) Representative colorplot depicting serotonin
oxidation (blue dot) after 60 minutes after L-DOPA (50 mg kg-1,i.p) administration. (C)
Representative CVs show a shift in oxidation potential, 60 minutes after L-DOPA
administration. (D) Average ± SEM predicted ratios over time after injection of saline over
control mice (red trace, n = 3), or levodopa (50 mg kg-1) for control mice (blue trace, n =
5) and MPTP-treated mice (purple trace, n =). The first time points after levodopa
administration when the predicted ratio is significantly lower than the control state is
marked with an asterisk (p < 0.005, two-way ANOVA with features of time after LD
administration and type of mice and Tukey-Krammer post-hoc analysis).
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release every 10 minutes for 120 minutes thereafter. Figure 4.7.A and B show
representative color plots from a saline treated mouse before and after L-DOPA, the shift
in oxidation potential is clear and verified with the CVs in Figure 4.7.C, implying a shift
from serotonin to dopamine release. Figure 4.7.D shows the mean ± SEM predicted ratio
of serotonin to dopamine in the CA2 region of the hippocampus of rodents for different
pharmacological paradigms. First, control mice after saline injection (red trace, n = 3 mice)
do not show a significant change in the ratio of both analytes. This means that after saline
injection, the evoked release of neurotransmitters resembles serotonin release. Following
L-DOPA administration (blue trace, n = 5 mice), the CNN model is able to predict a
sustained decrease of the relative ratio of serotonin to dopamine. This effectively means
that the evoked vesicular release of neurotransmitters is continuously transitioning from a
serotonin-rich release to a dopamine-rich release. For MPTP-treated mice (purple trace, n
= 5 mice), the effect of L-DOPA is analogous to control mice; a continuous decrease of the
relative ratio is present after LD administration.
A two-way ANOVA test between control or MPTP-treated and time after LD
administration was used to underpin the statistical differences between the predicted ratios.
Importantly, the analysis showed that there was a statistically significant effect of the group
in the predicted serotonin to dopamine ratios (two-way ANOVA, F = 4.15, p = 0.0433), as
well as in the time after LD administration (two-way ANOVA, F = 5.67, p < 0.0001).
However, no significance was found for the effect of the interference between both features
(one-way ANOVA, F = 0.72, p = 0.7434), suggesting that LD administration affects both
groups of mice similarly.

A Tukey-Krammer post-hoc multiple comparisons test was

performed to determine what values were significantly different. For control mice, 80 min
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is the earliest time after LD administration when the change of ratio is statistically
significant with respect to control (post-hoc test, ratio = 0.97 ± 0.02 vs. 0.75 ± 0.01, p =
0.0380). For MPTP-treated mice, this happens at 90 min after LD administration with
respect to the control mice (post-hoc test, ratio = 0.97 ± 0.02 vs. 0.76 ± 0.07, p = 0.0.0314).
We thus present the real-time conversion of the serotonin signal to dopamine after LDOPA.
4.4 Conclusion
The underlying serotonergic neurochemistry has been largely understudied in the
context of Parkinson’s Disease, however, there have been several hypotheses put forth.
First, that serotonin signaling might be deficient in PD, second that SSRIs are less effective
in PD patients and finally that LID is underpinned by the serotonergic system. We
evaluated evoked and ambient differences in a toxicological model of Parkinsonism and
found that mice receiving MPTP had significantly lower evoked and ambient serotonin
concentrations than controls. Furthermore, escit administration was unable to increase
serotonin concentrations to levels of control animals. Finally, using a novel neural network
we observe, in real-time, an increased ratio of dopamine to serotonin release in the
hippocampus following L-DOPA, suggesting that serotonergic neurons release dopamine
at the expense of serotonin. These results validate key prior hypotheses about the roles of
serotonin during PD and open an avenue of study to improve therapeutics for LID and
depression.
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CHAPTER 5
OVEROXIDATION VIA A NOVEL WAVEFORM INCREASES
ELECTRODE SENSITIVITY TO SEROTONIN1

1Buchanan,

A. M., Hashemi, P. Overoxidation via a Novel Waveform Increases Electrode

Sensitivity to Serotonin. Analyst. In preparation.
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5.0 Abstract
Serotonin detection using fast scan cyclic voltammetry has traditionally used a
specialized waveform with a 1.0 V upper limit (0.2 V to 1.0 V to -0.1 V to 0.2 V). However,
this waveform lacks sensitivity, making it difficult for many researchers to utilize. In this
study, we explore the use of an extended waveform with an upper limit of 1.3 V (0.2 V to
1.3 to -0.1 V to 0.2 V) to improve electrode sensitivity to serotonin. We investigate both
the use of the extended waveform to take serotonin measurements and its application as a
tool for electrochemical pretreatment. The 20 minute and 40 minute pretreatment times
showed the greatest increase in sensitivity in vitro, however there was no difference
between groups in vivo. Data collection on the extended waveform provided an enhanced
sensitivity in vivo compared to in vitro, while maintaining selectivity. This is hypothesized
to be due to amino acid polymerization on the electrode surface. These results provide new
waveform and electrochemical pretreatment options for detection of serotonin in vitro and
in vivo.
5.1 Introduction
Since fast scan cyclic voltammetry (FSCV) was first pioneered for the detection of
dopamine by Wightman and Millar,107 there have been many efforts to improve the
sensitivity of the technique for dopamine detection, including utilizing new electrode
materials,280, 281 introducing new coatings to the electrode surface,119, 282-284 and optimizing
waveform limits.285 In 2003, Wightman and colleagues extended the upper limit of the
dopamine waveform from 1.0 V to 1.4 V to increase electrode sensitivity.285 This increased
sensitivity when scanning to higher potentials has been observed to alter the surface
properties of the carbon fiber by increasing the surface oxides present. 286 Furthermore,
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going above 1.0 V has been shown to etch the carbon surface, preventing fouling through
continuous surface renewal.287 In vivo, we have previously shown that some of this
increased sensitivity may be due to the polymerization of amino acids on the electrode
surface.284
In our laboratory, we have optimized FSCV for the detection of in vivo serotonin.108
Over the past decade, we have used this technique to evaluate many different aspects of
serotonin neurochemistry, such as examining sex differences, investigating antidepressant
therapies, and mapping the architecture of serotonin circuits in multiple brain regions.143,
199, 200, 225, 232

However, serotonin FSCV has remained a niche technique because of the

difficulty associated with detection. Serotonin is highly regulated in the brain, compared
to dopamine (nM concentrations compared to µM concentrations). 197 Furthermore, the
serotonin waveform is not as sensitive as the dopamine waveform as it has an upper limit
of 1.0 V and does not undergo surface renewal. This upper limit might make the electrode
susceptible to fouling from metabolites such as the primary serotonin metabolite, 5hydroxyindole acetic acid (5-HIAA), as well as serotonin itself.125, 288
In this work, we explore the effects of electrochemical pretreatment with an
extended serotonin waveform (upper limit of 1.3 V) on serotonin data collection. We found
that following treatment, electrodes show a 2-fold or greater increase in sensitivity to
serotonin using FSCV. This increase is dependent upon the length of time cycled at 60 Hz.
We later replicated this result when we placed the electrodes in vivo into the CA2 region
of the hippocampus. However, in vivo, the increase in serotonin signal is no longer time
dependent. While in vitro increases in sensitivity are most likely due to activation of the
carbon fiber through an increase in the surface oxides necessary for electrochemical
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detection, in vivo, sensitivity is more complex. We have previously shown that in vivo
interactions between the carbon fiber and glutamate improve electrode sensitivity to
serotonin and dopamine.284 At potentials above 1.0 V, glutamate polymerizes on the
electrode surface, forming negatively charged polyglutamic acid (PGA).289, 290 Electrodes
coated with PGA present a morphological similarity to electrochemically pretreated
electrodes.
Using these findings, we propose use of a novel extended waveform optimized for
serotonin detection. This waveform with an upper limit of 1.3 V, increases sensitivity in
vitro and in vivo while maintaining selectivity. Furthermore, pretreatment with this
waveform increases sensitivity in vitro in a time dependent manner. This work allows us
to achieve our goal of making serotonin detection using FSCV more easily accessible to
researchers.
5.2 Materials and Methods
Chemicals and Reagents
Urethane (Sigma Aldrich) was dissolved in sterile saline (0.9%, Hospira) as a 25%
w/v solution and administered at 7 µL kg-1 via i.p. injection. Serotonin was dissolved
(Sigma-Aldrich, St. Louis, MO, USA) into Tris buffer to produce solutions with a
concentration of 100 nM. Tris Buffer consisted of 15 mM H2NC(CH2OH)2 HCl, 140 mM
NaCl, 3.25 mM KCl, 1.2 mM CaCl2, 1.25 mM NaH 2PO4 ·H2O, 1.2 mM MgCl2, and 2.0
mM Na2SO4 (Sigma-Aldrich). Interfering analytes dopamine (10 µM), adenosine (µM), 5HIAA (10 µM), DOPAC (20 µM), and ascorbic acid (400 µM) (Sigma Aldrich) were
dissolved in Tris buffer to attain the desired concentration.
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Electrode Fabrication
Carbon fiber microelectrodes (CFMs) were fabricated by aspirating a carbon fiber
(Goodfellow Corporation, Coraopolis, PA, United States) into a glass capillary (0.4 mm
internal diameter, 0.6 mm outer diameter, AM Systems, Carlsborg, WA, United States). A
carbon-glass seal was created by pulling the electrodes to a fine tip using a vertical pipette
puller (Narishige Group, Tokyo, Japan). The exposed carbon fiber was then cut to 150 µm.
Nafion was electroplated onto the electrode surface by application of a constant potential
(~1 V) for 30 s and then dried in an oven for 10 min at 70 °C.
Flow Injection Analysis
All flow injection analysis (FIA) was performed on an apparatus built in-house.
CFMs were placed in a flangeless short (PEEK P-335, IDEX, Middleboro, MA, USA),
with approximately 2 mm of the tip exposed outside of the nut. The nut containing the
CFM was placed in one end of a modified HPLC union (Elbow PEEK 3432, IDEX,
Middleboro, MA, USA). The stream containing the buffer was fastened to the other end of
the HPLC union. Two holes were drilled into back the union to allow for insertion of the
Ag/AgCl reference and to allow for waste flow. Analyte was injected into the system via a
six port HPLC loop injector (Cheminert Valve, VICI, Houston, TX, USA) to obtain a
rectangular plug. The flow was maintained at 2 mL min-1 by a syringe infusion pump (KD
Scientific, Model KDS-410, Holliston, MA, USA).
Animals and Surgical Procedure
All animal procedures and protocols were performed in accordance with
regulations of the Institutional Animal Care and Use Committee (IACUC) at the University
of South Carolina, which operates with accreditation from the Association for Assessment
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and Accreditation of Laboratory Animal Care (AAALAC). C57BL/6J mice at 6-14 weeks
of age were group housed on a 12 h light dark cycle with ad libitum access to food and
water.
Animals were anesthetized with urethane via i.p. injection prior to surgery.
Stereotaxic surgery was then performed with all coordinates taken in reference to bregma.
A CFM was lowered into the CA2 region of the hippocampus (AP: -2.91, ML: +3.35, DV:
-2.5 to 3.2) and compared to a pseudo Ag/AgCl reference electrode placed in the
contralateral hemisphere. A stimulating electrode (insulated stainless steel, diameter: 0.2
mm, untwisted, Plastics One, Roanoke, VA, United States) was placed into the medial
forebrain bundle (AP: -1.58, ML: +1.00, DV: -4.8)
Data Collection and Analysis
Serotonin was measured using FSCV either in an FIA apparatus or on anesthetized
mice. All measurements were collected using a Dagan potentiostat (Dagan Corporation,
Minneapolis, NM), custom built hardware interfaced with PCIe 6431 and PCI 6221
DAC/ADC cards (National Instruments, Austin, TX), and a Pine Research headstage (Pine
Research Instruments, Durham, NC). Either the “traditional” serotonin waveform (0.2 V
to 1.0 V to -0.1 V to 0.2 V, scan rate = 1000 V/s) or the “extended” serotonin waveform
(0.2 V to 1.0 V to -0.1 V to 0.2 V, scan rate = 1000 V/s) was applied using WCCV 3.06
software.
For pretreatment experiments, four measurements were taken on the traditional (1.0
V) waveform. The extended (1.3 V) waveform was then applied at 60 Hz for either 2 min,
10 min, or 20 min before it was switched back to the traditional waveform and cycled at
60 Hz for 10 minutes followed by 10 Hz for 10 minutes. Files were then again taken on the
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traditional waveform. The extended waveform was also used to take measurements. For
these experiments, four measurements were taken on the traditional waveform. The system
was then switched to the extended waveform and cycled for 60 Hz for 10 minutes followed
by 10 Hz for 10 minutes. Collection occurred on the extended waveform. For animal
experiments, a biphasic electrical stimulation (60 Hz, 360 µA, 2 ms in width) was applied
for 2 s through a linear constant current stimulus isolator (NL800A Neurolog, Medical
Systems Corp, Great Neck, NY) to evoke serotonin release. Data were collected and
filtered using WCCV software (zero phase, Butterworth, 3 kHz low pass filter). The
obtained currents were converted to concentration using a previously reported calibration
factor (11 µM nA-1).108
Statistical Analysis
All error is reported as mean  standard error of the mean (SEM). The Grubbs test
was used to test for outliers that fall outside of the normally distributed population.
Significance was determined by a two-tailed paired t-test and taken as p < 0.05.
5.3 Results and Discussion
5.3.1 Novel waveform provides increased serotonin sensitivity
The serotonin waveform first optimized by Jackson et al.,198 and later characterized
in vivo by Hashemi et al.108 has undergone no optimization in the last 25 years. As with the
extension of the dopamine waveform, we have increased the upper limit of the serotonin
waveform from 1.0 V to 1.3 V, in vitro (Figure 5.1) to improve sensitivity. The upper limit
of 1.3 V was chosen because it represents the oxidation potential of carbon, thus maximizes
overoxidation of the electrode surface without causing extensive damage to the carbon
fiber. As illustrated by Takmakov et al.287 when scanning to 1.3 V or above, the carbon
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fiber is etched, constantly renewing the electrode surface. This continuous renewal
prevents electrode biofouling by molecules such as 5-HIAA and serotonin. However,
scanning to 1.4 V causes this etching phenomenon to occur at a much higher rate (~10
times faster) resulting in complete disappearance of the carbon fiber within 6 hours. At 1.0
V, little to no etching occurs.

Figure 5.1. (A) The “traditional” serotonin waveform with an upper limit of 1.0 V along
with representative colorplot and CV. Serotonin oxidative peak is seen at ~0.6 V in Tris
buffer. (B) The “extended” serotonin waveform with an upper limit of 1.3 V and
representative color plot and CV. The serotonin oxidative peak is seen at the same potential
as the traditional waveform (~0.6 V). Approximately a two-fold increase is seen from the
traditional to the extended waveform for 100 nM [5-HT] in Tris buffer.
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As seen previously with the extension of the dopamine waveform, extending the
serotonin waveform to 1.3 V increases the sensitivity of the electrode (by ~2 fold, 10.6 ±
2.0 to 16.9 ± 2.4 nA, p < 0.05, n = 4) in vitro. To maintain selectivity and sensitivity, only
the upper limit of the waveform was altered. The remaining aspects of the waveform were
unchanged. The holding potential was held at 0.2 V for both waveforms as this potential
has been previously shown to have the highest rate of adsorption for serotonin (k= 4.22
±0.33 s-1).125 The scan rate was maintained at 1000 V/s to prevent the adsorption of
kinetically slower dopamine and serotonin oxidative byproducts such as p-quinone
amine.108, 198, 291
5.3.2 Extended waveform maintains serotonin selectivity
It is critical for an electrochemical method to exhibit a high selectivity towards the
analyte of interest. One risk of increasing the potential window for a waveform, is
decreasing selectivity.285 To test the selectivity of the extended waveform, several
neurotransmitters and biological molecules were selected as potential interferants. Each
interferant was investigated at a biologically relevant concentration. 108, 125 The CVs for
each interferant are presented for both the traditional (1.0 V) and extended (1.3 V)
waveform in Figure 5.2. The CVs of interfering molecules are exhibited by the red traces
and the serotonin peak is presented as an overlaying dotted line for each interferant.
For both the 1.0 V and 1.3 V waveforms, the serotonin peak is observed at ~0.6 V.
A small peak is detected at ~ 0.8 V across both waveforms for dopamine. However, this
peak is much smaller than the serotonin peak and is much broader due to dopamine’s
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Figure 5.2. CVs for potential interfering analytes. CVs for interfering analytes (red traces)
are compared to the CV for serotonin (gray dotted line) for each waveform. Interreferences
shown are dopamine (10 µM), adenosine (10 µM), 5-HIAA (10 µM), DOPAC (20 µM),
and ascorbic acid (400 µM).
slower adsorption kinetics.292 Norepinephrine was not tested in this study, however, it has
been shown to have a nearly identical electrochemical profile to dopamine, and is released
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at much lower concentrations.293 No peak is observed for adenosine. This is expected as
adenosine oxidation peaks are typically observed around 1.4 V with a secondary oxidation
at approximately 1.0 V.294 A small peak is observed for each waveform for the serotonin
metabolite, 5-HIAA. This has been observed previously, however, it is only 10% of the
recorded serotonin signal despite being ten times the concentration. Furthermore, we do
not expect it to be transiently released in the brain. No legible oxidation peaks are observed
for the dopamine metabolite, DOPAC, or for ascorbic acid for either waveform. This data
shows that the extended serotonin waveform is equally as selective as the traditional
waveform for serotonin over common interferants.
5.3.3 Time-dependent treatment with the extended waveform and effects on sensitivity
Previous studies show that electrochemical pretreatment of carbon fibers at high
potentials increases the sensitivity of the electrode surface for dopamine,295, 296 irreversibly
altering the chemical make-up of the carbon surface. Here we compare increased sensitivity
following electrochemical pretreatment with measurements taken on the extended
waveform. The experimental paradigm is outlined in Figure 5.3A. For pretreatment
experiments, measurements were taken on the traditional waveform for each electrode
prior to pretreatment for comparison. Pretreatment occurred by cycling the electrode on the
extended waveform for a specific period of time. Measurements were then taken on the
traditional waveform. For measurements taken on the 1.3 V waveform, the electrode was
cycled on the extended (1.3 V) waveform for 10 minutes at 60 Hz, however, the waveform
was not returned to the 1.0 V waveform for data collection.
Following treatment with the extended waveform, Figure 5.3.B shows that all four
treatment paradigms significantly increase the sensitivity of the electrode to serotonin. The
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Figure 5.3. (A) Illustration of pretreatment paradigm. Electrodes were cycled on the
extended waveform for 2 min, 10 min, 20 min, or 40 min, at a frequency of 60 Hz before
switching back to the traditional waveform. (B) The current is shown for each
electrochemical pretreatment group before and after pretreatment. All groups exhibit a
significant increase in serotonin response following pretreatment. For 2 min, 10 min, 20
min, and the 1.3 V WF, p < 0.05. For 40 min, p < 0.0001. (C) The percent increase after
electrochemical treatment. The 40 min treatment is significantly increased compared to
the 1.3 V WF. (p < 0.05). (n = 4 for each group)
two minute pretreatment (increase from 12.1 ± 1.9 to 18.1 ± 2.3 nA, p < 0.05), ten minute
pretreatment (9.7 ± 1.4 to 15.4 ± 1.2 nA, p < 0.05), and extended waveform (10.6 ± 2.0 to
16.9 ± 2.4 nA, p < 0.05) all have similar increases in serotonin signals, while the 20 minute
(12.0 ± 1.2 to 26.0 ± 3.0 nA, p < 0.05) and 40 minute (8.6 ± 2.0 to 26.5 ± 2.3 nA, p <
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0.0001) pretreatments have a markedly larger increase. The percent increase in serotonin
signals following treatment are shown in Figure 5.3.C. The two minute (0.58 ± .18 nA)
and 10 minute (0.54 ± 0.065 nA) have similar percent increases to the 1.3 V waveform
(0.59 ± 0.13 nA). The 40 minute (2.45 ± .7 nA) treatment is significantly different from the
percent increase of the 1.3 V waveform (p < 0.05), while the 20 minute treatment (1.21 ±
.26) is trending towards significance (p = 0.17).
The lower increase in sensitivity of the extended waveform compared to the 20 and
40 minute treatments is most likely due to the time cycled at 60 Hz. Cycling at higher
frequencies allows for the waveform to be applied more often. At 60 Hz, the waveform is
applied six times more often than at 10 Hz, allowing for the waveform to reach the upper
limit of 1.3 V more frequently. When measurements are performed on the extended
waveform, less increase is seen because the waveform is only cycled at 60 Hz for ten
minutes. It is expected that if this period were to increase to 20 minutes, it would have
similar behavior to the 20 minute pretreatment. Because there are no other confounding
factors in vitro, the increase in serotonin signal following electrochemical treatment is most
likely due to a combination of overoxidation at the electrode surface285 and surface renewal
preventing fouling.287

5.4.4 In vivo detection of serotonin is enhanced with extended waveform treatment
Because the major application for serotonin detection using FSCV is in vivo, we
wanted to evaluate the effect of extended waveform treatment in brain tissue. For these
experiments, electrodes were placed in the CA2 region of the hippocampus. This is a brain
region with well characterized serotonin FSCV measurements.232 As with the in vitro
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experiments, serotonin measurements were collected before and after electrochemical
treatment. To limit the number of animals used, the 10 minute and 20 minute pretreatment
times were selected and compared to measurements collected on the extended waveform.

Even though it produced the largest increase, the 40 minute treatment was not chosen

Figure 5.4. (A,B) Representative colorplots of serotonin oxidation for in vivo
measurements taken on the traditional and extended waveform respectively. The vertical
dashed line produces the CVs overlaid in the top right corner of each colorplot. The
horizontal dashed line produces the current vs time curves presented in C, D, and E. (C-E)
Current vs time curves for the 10 min and 20 min pretreatments (C and D respectively) and
files taken on the 1.3 V waveform (E) both before and after treatment. (F) The current is
shown for each electrochemical pretreatment group before and after pretreatment. The 10
min (p < 0.01) and the 1.3 V waveform (p < 0.05) show significant increase in current
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following treatment. (G) The percent increase after electrochemical treatment. No
difference between each of the three groups. (n = 4 for each group).
because of the impracticality of cycling for a total duration of an hour before performing
every experiment.
Figure 5.4.A and B show representative color plots for in vivo serotonin
measurements collected on an electrode using the 1.0 V waveform and 1.3 V waveform
respectively. The current vs time curves are presented in Figure 5.4.C-E. Each of the 10
minute, 20 minute, and 1.3 V waveform show marked increase following treatment, while
maintaining the characteristic release and reuptake profile seen on the traditional
waveform. The max amplitudes of each current vs time curve were determined and
compared in Figure 5.4.F. The 10 minute pretreatment (increase from 0.83 ± 0.061 to 1.97
± 0.096 nA, p < 0.01) and collection on the 1.3 V waveform (1.47 ± 0.21 to 3.24 ± 0.57
nA, p < 0.05) both show significant increase in serotonin signal amplitude, while the 20
minute pretreatment (1.58 ± 0.21 to 3.47 ± 0.85 nA, p = 0.097) shows a trend towards
significance. There is no difference observed for the 10 minute (1.43 ± 0.29 nA) or 20
minute pretreatments (1.29 ± .49 nA) compared to data collected on the extended waveform
(1.21 ± 0.26 nA) for percent increase following treatment (Figure 5.4.G.)
The brain environment is far more complex than the matrix used for in vitro
experiments. We hypothesize that this complexity is responsible for the lack of differences
seen between the three treatment groups in vivo. In a previous study we have shown that
the amino acid and neurotransmitter, glutamate, polymerizes to the electrode surface at a
voltage above 1.0 V.284 This irreversible polymerization increases the sensitivity of the
electrode to both serotonin and dopamine. Other amino acids abundant in the brain such as
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GABA and glycine may also polymerize to the electrode surface and are being
investigated.
5.4 Conclusion
Both collecting measurements on and pretreating with the extended waveform
increase the sensitivity of the electrode to serotonin. In vitro, the longer time periods of 20
minutes and 40 minutes have a greater increase in signal amplitude. This is attributed to an
increased number of times reaching the upper limit of 1.3 V, causing more overoxidation
and etching of the carbon surface. In vivo, enhanced signal increase is seen, however, no
difference is seen across the three treatment groups. We attribute this to a combination of
overoxidation, etching, and amino acid polymerization.
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CHAPTER 6
CONCLUSIONS AND PROSPECTS
Serotonin is a monoamine neuromodulator with a wide variety of functions and
implications in many different disorders. Of particular interest in this work is serotonin’s
role in mood disorders associated with Parkinson’s Disease. There are many aspects of
dynamic serotonergic neurochemistry that have not yet been explored because of a lack of
tools for real time detection. Fast scan cyclic voltammetry (FSCV) is one tool that provides
selective, fast, and direct detection of neurotransmitters. However, serotonergic detection
using FSCV is relatively new and as such, there are many unexplored subjects in terms of
fast serotonin dynamics. Furthermore, there is much room for advancement and
optimization in the technique to improve aspects such as sensitivity, selectivity, and
temporal resolution.

This work continues previous Hashemi lab investigations into

serotonin dysfunction in diseases states.
In this dissertation, I first discussed different techniques for the determination of
reuptake kinetics for the monoamines of dopamine, serotonin, and norepinephrine (Chapter
2). These monoamines have an intricate and interactive relationship in terms of transporter
affinity. I then reviewed serotonin FSCV and previous studies using the technique (Chapter
3). Next, I investigated serotonin dynamics in a toxicological model of PD (Chapter 4). I
validated three main hypotheses. 1) Serotonin signaling is impaired during PD. 2) A class
of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) are less
effective in PD animals. 3) L-DOPA administration causes an increase in dopamine release
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at the expense of serotonin. Using a combination of electrochemical techniques,
mathematical modeling, and machine learning, we were able to evaluate the effect of
certain drugs on serotonin release, reuptake, and ambient levels in the 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinsonism. We found that MPTP
animals have both lower evoked and ambient concentrations of serotonin than mice
administered saline vehicle. Furthermore, we found that the SSRI, escitalopram, is less
effective in mice administered MPTP. Then using a novel convoluted neural network we
were able to predict the relative ratio of serotonin to dopamine following L-DOPA
administration. We found that following drug administration, dopamine is released at a
higher rate in the hippocampus than serotonin. These findings verify key hypotheses in PD
associated serotonergic dysfunction. Finally, I evaluated a novel waveform to optimize and
improve serotonin detection using FSCV (Chapter 5). After finding that the MPTP mice in
chapter 4 released lower concentrations of evoked serotonin, it because evident that we
needed more sensitive tools for future experiments. By extending the waveform from an
upper limit of 1.0 V to 1.3 V were were able to increase electrode sensitivity to serotonin
by ~2-fold in vitro and in vivo while maintaining selectivity. Furthermore we show that
electrochemical pretreatment by potentials above 1.0 V increase sensitivity in vivo, most
likely through a combination of overoxidation of the carbon fiber and amino acid
polymerization to the electrode surface.
This dissertation furthered our understanding of serotonergic neurochemistry by
moving from studies in healthy mice to those in diseased states. We’ve shown that
serotonin FSCV can be used in the future as a robust tool in the evaluation of
neurotransmitter dysfuntion across different disorders. Future studies will need to evaluate
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evoked and ambient serotonin in additional toxicological and genetic models of PD, as well
as additional depressive and neurodegenerative disorders. I applied serotonin
electrochemistry in one animal model of PD. However, we plan to evaluate additional wellestablished models to confirm that our findings are more than just an artifact of the model
chosen. We also plan to measure evoked histamine in this model as well as additional ones
to further investigate the role of neuroinflammation in PD.
Overall, this dissertation showcased the ability of FSCV to investigate the
underlying neurochemistry of disease states. It also demonstrated that FSCV and FSCAV
are important tools in the evaluation of pharmaceuticals on serotonergic transmission. By
continuing to improve and optimize our analytical tools, we can continue to answer
fundametal neuroscience questions underlying disease.
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APPENDIX A
SUPPLEMENTAL MATERIAL FOR CHAPTER 4
ANOVA analyses on max amplitude of evoked serotonin release following
escitalopram. A two-way ANOVA with features of type of mice and time of the treatment
paradigm, if any (control and escit separated by time after injection) was used to check
statistical differences in maximum amplitude of the evoked release for the different
pharmacological paradigms.
Table A.1: Extract of the list of names of groups and indexes of the analysis of variance.
Group

Number

Effect 1

Effect 2

Control

Control

1

Control

MPTP

2

Escit 30 min Control

3

Escit 30 min MPTP

4

Escit 60 min Control

5

Escit 60 min MPTP

6
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Table A.2: Analysis of variance results for the estimations of maximum amplitude of
serotonin evoked release. Shows that a significant effect of the treatment (control and escit)
and the type of mice (control and MPTP) were found in the maximum amplitude of evoked
release of serotonin. After that, a Tukey-Kramer post-hoc multiple comparison test was
performed. An extract of the matrix of multiple comparisons p values are shown in Table
A.3, and p values in bold are reported in the main manuscript.
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Treatment

3.2668e+04

8

4.0835e+03

9.9172

4.0345e-10

Type

3.0542e+04

1

3.0542e+04

74.1745

9.4267e-14

Interference

7.0781e+03

8

884.7632

2.1487

0.0377

Error

4.2000e+04

102

411.7640

-

-

Total

1.0762e+05

119

-

-

-

Table A.3: Analysis of variance results for the in vivo predictions maximum amplitude of
evoked serotonin release. An extraction of the pairwise comparison between groups is
provided for ease of read (18 different groups were compared). All probability values are
available upon request, as well as post-hoc comparisons across individual effects.
Tukey-Kramer post-hoc multiple tests
Pr > |t| for H0: Mean max amplitude (i) = Mean max amplitude (j)
i/j

1

2

3

4

1

-

0.0336

0.0005

0.9999 0.0162 1.000

2

0.0336 -

3

0.0005 < 0.0001 -

0.0993 1.000

4

0.9999 0.9306

0.0993

-

5

0.0162 0.0002

1.000

0.4761 -

6

1.000

0.0359

1.000

0.9958

5

6

< 0.0001 0.9306 0.0002 0.9958
0.0359

0.4761 1.000
0.0095

0.0095 -

ANOVA analyses on clearance rate of evoked serotonin release following
escitalopram. A two-way ANOVA with features of type of mice and time of the treatment
paradigm, if any (control and escit separated by time after injection) was used to check
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statistical differences in clearance rate of the serotonin reuptake curve for the different
pharmacological paradigms.

Table A.4: Extract of the list of names of groups and indexes of the analysis of variance.
Group

Number

Effect 1

Effect 2

Control

Control

1

Control

MPTP

2

Escit 30 min Control

3

Escit 30 min MPTP

4

Escit 60 min Control

5

Escit 60 min MPTP

6

Table A.5: Analysis of variance results for the estimations of clearance rate of serotonin
reuptake curve. Shows that a significant effect of the treatment (control and escit) and the
type of mice (control and MPTP) were found in the clearance rate of evoked release of
serotonin. After that, a Tukey-Kramer post-hoc multiple comparison test was performed.
An extract of the matrix of multiple comparisons p values are shown in Table S.6, and p
values in bold are reported in the main manuscript.
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Treatment

1.0291e+04

8

1.2863e+03

31.3820

2.8780e-24

Type

210.4289

1

210.4289

5.1338

0.0256

Interference 436.9959

8

54.6245

1.3327

0.2359

Error

4.1809e+03

102

40.9890

-

-

Total

1.5104e+04

119

-

-

-

118

Table A.6: Analysis of variance results for the in vivo clearance rate of serotonin release.
An extraction of the pairwise comparison between groups is provided for ease of read (18
different groups were compared). All probability values are available upon request, as well
as post-hoc comparisons across individual effects.

Tukey-Kramer post-hoc multiple tests
Pr > |t| for H0: Mean clearance rate (i) = Mean clearance rate (j)
i/j

1

2

3

4

5

6

1

-

1.000

< 0.0001

< 0.0001

< 0.0001

0.0008

2

1.000

-

< 0.0001

< 0.0001

< 0.0001

0.0001

3

< 0.0001

< 0.0001

-

1.000

0.9998

0.9997

4

< 0.0001

< 0.0001

1.000

-

1.000

0.9716

5

< 0.0001

< 0.0001

0.9998

1.000

-

0.7691

6

0.0008

0.0001

0.9997

0.9716

0.7691

-

ANOVA analyses on the in vivo serotonin basal estimations following escitalopram. A
two-way ANOVA with features of type of mice and time of the treatment paradigm
(control, saline and time after escit administration) was used to underpin the differences
between both cohorts of mice and their response to escit administration.
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Table A.7: Extract of list of names of groups and indexes of the analysis of variance.
Group

Number

Effect 1

Effect 2

Control (0-30 min) Control

1

Control (0-30 min) MPTP

2

Saline (30-60 min) Control

3

Saline (30-60 min) MPTP

4

Escit 120 min

Control

5

Escit 120 min

MPTP

6

Table A.8: Analysis of variance results for the estimations of absolute concentration of
serotonin. Shows that a significant effect of the treatment (Control, Saline and escit) and
the type of mice (Control and MPTP) were found in the basal in vivo estimations of
serotonin ambient levels. After that, a Tukey-Kramer post-hoc multiple comparison test
was performed. An extract of the matrix of multiple comparisons p values are shown in
Table A.9, and p values in bold are reported in the main manuscript.
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Treatment

1.1393e+05

58

1.9643e+03

2.8935

1.9172e-11

Type

1.7462e+05

1

1.7462e+05

257.2188

6.6609e-52

Interference

1.4631e+04

58

252.2562

0.3716

1.000

Error

7.0737e+05

1042

678.8600

-

-

Total

1.0620e+06

1159

-

-

-

120

Table A.9: Analysis of variance results for the in vivo predictions of absolute serotonin
concentration. An extraction of the pairwise comparison between groups is provided for
ease of read (120 groups were compared). All probability values are available upon request,
as well as post-hoc comparisons across individual effects.
Tukey-Kramer post-hoc multiple tests
Pr > |t| for H0: Mean serotonin (i) = Mean serotonin (j)
i/j

1

2

3

4

5

6

1

-

< 0.0001

1.000

1.000

0.0269

0.1444

2

< 0.0001

-

1.000

1.000

0.0174

0.0243

3

1.000

1.000

-

1.000

0.9146

0.9716

4

1.000

1.000

1.000

-

0.0399

0.0471

5

0.0174

1.000

0.9146

0.0399

-

1.000

6

0.0243

1.000

0.9716

0.0471

1.000

-

ANOVA analyses on the in vivo ratio estimations using the convolutional neural
network model. A two-way ANOVA with features of type of mice and time after levodopa
administration was used to study the differences in treatment response between mice.

Table A.10: Extract of list of names of groups and indexes of the analysis of variance.
Group

Number

Effect 1 Effect 2
Control

0 min after LD treatment

1

MPTP

0 min after LD treatment

2

Control

60 min after LD treatment

3

MPTP

60 min after LD treatment

4

Control

120 min after LD treatment 5

MPTP

120 min after LD treatment 6
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Table A.11: Analysis of variance results for the estimations of ratio of serotonin to
dopamine. Shows that a significant effect of time after LD administration and the type of
mice (Control and MPTP) were found in the relative ratio estimations. The interference
does not have a statistically significant effect, meaning that LD treatment may have an
analogous effect for both types of mice. After that, a Tukey-Kramer post-hoc multiple
comparison test was performed. An extract of the matrix of multiple comparisons p values
are shown in Table S.12, and p values in bold are reported in the main manuscript
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Type

0.0611

1

0.06114

4.15

0.0433

Time

1.0851

13

0.08347

5.67

0

Interference

0.1374

13

0.01473

0.72

0.7434

Error

2.2677

154

0.01473

-

-

Total

4.0663

181

-

-

-

Table A.12: Analysis of variance results for the in vivo predictions of ratio of serotonin to
dopamine. An extraction of the pairwise comparison between groups is provided for ease
of read ( groups were compared). All probability values are available upon request, as well
as post-hoc comparisons across individual effects.
Tukey-Kramer post-hoc multiple tests
Pr > |t| for H0: Mean serotonin (i) = Mean serotonin (j)
i/j

1

2

3

4

5

6

1

-

0.9999

0.9984

0.2617

< 0.0001

0.0032

2

0.9999

-

0.9985

1.000

0.2139

0.8916

3

0.9984

0.9985

-

0.9998

0.9989

1.000

4

0.2617

1.000

0.9998

-

0.3283

0.9556

5

< 0.0001

0.2139

0.9989

0.3283

-

1.000

6

0.0032

0.8916

1.000

0.9556

1.000

-

ANOVA analyses on differences in sex and MPTP administration time for
maximum amplitude of the release. A two-way ANOVA with features of sex of mouse
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and time between the signal acquisition was used to study if there was any effect of the sex
or acquisition time in the maximum amplitude of evoked signals for saline and MPTP mice.

Table A.13: Extract of list of names of groups and indexes of the analysis of variance.
Group

Number

Effect 1

Effect 2

7 to 13 days after MPTP injection Male

1

4 to 21 days after MPTP injection Female

2

4 to 21 days after MPTP injection Male

3

7 to 13 days after MPTP injection Female

4

Table A.14: Analysis of variance results for the estimations of ratio of serotonin to
dopamine.
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Time

15.06

1

15.06

0.17

0.6865

Sex

80.55

1

80.55

0.90

0.3554

Interference

21.95

1

21.95

0.22

0.6264

Error

1611.42

18

89.52

-

-

Total

1832.21

21

-

-

-

ANOVA analyses on differences in sex and MPTP administration time for
clearance rate of the serotonin reuptake curve. A two-way ANOVA with features of
sex of mouse and time between the signal acquisition was used to study if there was any
effect of the sex or acquisition time in the clearance rate of evoked signals for saline and
MPTP mice.
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Table A.15: Extract of list of names of groups and indexes of the analysis of variance.
Group

Number

Effect 1

Effect 2

7 to 13 days after MPTP injection Male

1

4 to 21 days after MPTP injection Female

2

4 to 21 days after MPTP injection Male

3

7 to 13 days after MPTP injection Female

4

Table A.16: Analysis of variance results for the estimations of ratio of serotonin to
dopamine.
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Time

0.46

1

0.46

0.55

0.4677

Sex

0.31

1

0.31

0.37

0.5518

Interference

0.01

1

0.01

0.02

0.9022

Error

15.00

18

0.83

-

-

Total

16.75

21

-

-

-
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APPENDIX B
NEURAL NETWORK TRAINING FOR CHAPTER 4
Training of Convolutional Neural Network (CNN)
Figure B.1A shows the training and validation loss of the convolutional neural
network for 500 iterations. The validation loss follows the training loss closely. Most of
the decrease takes part in the 50 first epochs, although the decrease is sustained until the
end of the training. Figure B.2B shows the true vs. predicted values of the unseen test
dataset. The CNN is able to accurately predict the relative ratios of the synthetic colorplots.

Figure B1: Training and validation loss and test ratio predictions of convolutional
neural network. (A, C) Root mean square error (cost function) progression by iteration of
the training and validation datasets during the total 500 epochs of the training. (B) True vs.
predicted values of the test dataset and RMSE between the true labels and the predicted
labels. The whole test dataset consisted of 7800 colorplots. The blue vertical line shows
the ideal response, where true values are equal to predicted values, while the scatter black
dots represent the CNN predictions. The number of shown scatter values is reduced by a
1/8 ratio for visualization purposes

125

